Clinical trial register · Spain

Clinical Trials in A Coruña, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Spain and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV

Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5875 matching records held by the registry are in this view. Synced 11 Oct 2026, 03:18 UTC

5875

Studies in scope

all four open statuses

3096

Recruiting now

open to new participants

1137

Lead sponsors

across recruiting studies

Top sites

Barcelona 3238 Madrid 3046 Valencia 1215 Seville 1054 Málaga 746

Trials with a site in A Coruña

Status

Study

Lead sponsor

Phase

Enrol

Sites in Spain

Start

Not yet open

An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of ALXN2220 in Adults With Transthyretin Amyloid Cardiomyopathy

NCT07789483Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

DrugCliramitug

Alexion Pharmaceuticals, Inc.

Phase 3

1,180

Jaén, Málaga, Palma de Mallorca, Salamanca, Barcelona, L'Hospitalet de Llobregat, Valencia, A Coruña

2027-11-23

Not yet open

A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis

NCT07335562Systemic Sclerosis

DrugsZola-cel·Nintedanib·Tocilizumab·Fludarabine

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Phase 3

A Coruña, Barcelona, Málaga

2027-02-03

Not yet open

A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity

NCT07861100Cardiovascular Risk, Obesity

DrugZenagamtide

Novo Nordisk A/S

Phase 3

8,500

Marbella, A Coruña, Barcelona, Boadilla del Monte, Cáceres, Córdoba, El Palmar, Granada

2026-10-26

Recruiting

A Study of BMS-986528 in Participants With Refractory Rheumatoid Arthritis

NCT07412704Arthritis, Rheumatoid

Bristol-Myers Squibb

Phase 1/2

A Coruña, Córdoba

2026-09-15

Recruiting

Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)

NCT07680790Non-Small Cell Lung Cancer

DrugsIza-bren·Osimertinib·Pemetrexed·Cisplatin

Bristol-Myers Squibb

Phase 3

850

Majadahonda, Seville, A Coruña, Jaén, Jerez de la Frontera, Madrid, Málaga, Valencia

2026-09-08

Recruiting

A Study of the Long-term Safety and Efficacy of Danicamtiv in Adults With Symptomatic Genetic and Familial Dilated Cardiomyopathy

NCT07771465Symptomatic Genetic Dilated Cardiomyopathy (DCM)

DrugDanicamtiv

Kardigan, Inc.

Phase 3

332

A Coruña, Barcelona, Madrid, Málaga, Murcia, Palma de Mallorca, Seville

2026-08-26

Recruiting

AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications

NCT07797335Type 2 Diabetes, Cardiovascular Risk

DrugZenagamtide

Novo Nordisk A/S

Phase 3

1,778

A Coruña, Barcelona, Móstoles, Sanlúcar de Barrameda, Santiago de Compostela, Segovia, Valencia

2026-08-24

Recruiting

A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight

NCT07784270Obesity or Overweight, Diabetes Mellitus, Type 2

DrugLenbelintide

AstraZeneca

Phase 3

1,500

A Coruña, Alzira, Barcelona, Ferrol, Lleida, Málaga, Oviedo, Segovia

2026-08-20

Recruiting

Real-World Effectiveness and Safety of Pegcetacoplan in Patients With C3G or IC-MPG: A Multi-Country Study

NCT07746895C3 Glomerulopathy (C3G), Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)

DrugPegcetacoplan

Swedish Orphan Biovitrum

Phase 4

150

A Coruña, Barcelona, Las Palmas, Madrid, Málaga, Valencia

2026-08-05

Recruiting

BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)

NCT07625644Small Cell Lung Cancer Extensive Stage, Small-cell Lung Cancer, Small Cell Carcinoma, Sclc

DrugsEtoposide·Atezolizumab·Carboplatin

SystImmune Inc.

Phase 3

550

A Coruña, Barcelona, Las Palmas de Gran Canaria, Madrid

2026-08-04

Active, closed

Respiratory Physiotherapy for Patients With Bronchiectasis

NCT07733323Bronchiectasis Adult

Yolanda Sanesteban Hermida

Observational

270

A Coruña

2026-07-07

Not yet open

Optimizing the Use of Aspirin for the Prevention of Preeclampsia

NCT07665853Preeclampsia

Hospital Universitari Vall d'Hebron Research Institute

Phase 3

15,160

Granada, Barcelona, Girona, Tarragona, Barakaldo, A Coruña, Alicante, Burgos

2026-07-01

Recruiting

A Clinical Trial of MK-7262 and Enlicitide in Participants With High Lipoprotein(a) (MK-7262-004)

NCT07614984Lipoprotein(a)

DrugsHRS-5346·Enlicitide·Enlicitide Decanoate

Merck Sharp & Dohme LLC

Phase 2

750

A Coruña, Castilleja de la Cuesta, Barcelona, Madrid, Seville

2026-06-30

Recruiting

A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM

NCT07667803Weight Management

DrugElecoglipron

AstraZeneca

Phase 3

4,500

A Coruña, Almería, Badalona, Barcelona, León, Madrid, Santander, Santiago de Compostela

2026-06-29

Recruiting

A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity

NCT07595549Obesity, Overweight and/or Obesity, Overweight

DrugBerobenatide

Pfizer

Phase 3

954

Madrid, A Coruña, Pozuelo de Alarcón, Seville

2026-06-10

Recruiting

An Efficacy and Safety Study of Cenegermin Ophthalmic Solution Compared With Vehicle in the Treatment of PCED

NCT07519902Persistent Corneal Epithelial Defect

DrugCenegermin

Dompé Farmaceutici S.p.A

Phase 3

150

A Coruña, Cardona, Badalona, Barcelona, Madrid, Málaga, Seville, Valencia

2026-06-02

Recruiting

A Study to See if Lepodisiran Can Reduce Plaque in Coronary Arteries of Adults With Elevated Lp(a) Who Have Had Heart Events or Are at High Risk

NCT07613294Atherosclerosis, Cardiovascular Diseases, Lipoprotein(a)

DrugLepodisiran

Eli Lilly and Company

Phase 3

252

A Coruña, Barcelona, Córdoba, Las Palmas de Gran Canaria, Madrid, Seville, Valencia

2026-06-01

Active, closed

Effects of Transcutaneous Vagus Nerve Stimulation in Parkinson´s Disease

NCT07588191Transcutaneous Vagal Nerve Stimulation (tVNS), Parkinson Disease (PD)

Universidade da Coruña

Not applicable

A Coruña

2026-05-25

Recruiting

A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight

NCT07564414Obesity, Type 2 Diabetes

DrugsCagriSema·Semaglutide

Novo Nordisk A/S

Phase 3

2,500

A Coruña, Antequera, Barcelona, Centelles (Barcelona), Girona, Madrid, Manresa, Málaga

2026-05-21

Recruiting

Sarilumab Efficacy and Safety in Adults With Early Polymyalgia Rheumatica

NCT07286214Polymyalgia Rheumatica

DrugSarilumab

Sanofi

Phase 4

300

Barcelona, A Coruña, Madrid, San Cristóbal de La Laguna, Málaga, Sabadell

2026-05-12

Recruiting

An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)

NCT07517263Cardiovascular Disease and Lipoprotein(a)

DrugPelacarsen

Novartis Pharmaceuticals

Phase 3

5,700

Santiago Compostela, Seville, Badalona, L'Hospitalet de Llobregat, Santander, Cáceres, Reus, A Coruña

2026-05-11

Recruiting

A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity

NCT07567001Obesity, Heart Failure

DrugNNC0487-0111

Novo Nordisk A/S

Phase 3

5,610

Sant Joan Despí, Valencia, A Coruña, Alcorcón, Antequera, Badalona, Barcelona, Bilbao

2026-05-11

Recruiting

A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies

NCT07415031Solid Tumors

DrugsAdagrasib·Fluorouracil·Leucovorin·Irinotecan

Mirati Therapeutics Inc.

Phase 2

170

A Coruña, Palma, Barcelona, Badalona, Santander, Madrid, Pamplona, Valencia

2026-05-06

Not yet open

REACTION-VAD Trial: Remote Exercise Training Via Telemedicine in Patients With Long-Term Ventricular Assist Devices

NCT07611188Heart Failure, Advanced Heart Failure, Left Ventricular Assist Device, LVAD

Puerta de Hierro University Hospital

Not applicable

Seville, Salamanca, Barcelona, A Coruña, Santiago de Compostela, Madrid, Majadahonda

2026-05

Recruiting

AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain

NCT07509307Obesity, Overweight, Osteoarthritis, Knee

DrugNNC0487-0111

Novo Nordisk A/S

Phase 3

400

A Coruña, Badalona, Ferrol, Madrid, Málaga, San Sebastián de Los Reyes (Madrid), Santander, Santiago de Compostela

2026-04-20

Recruiting

Visugromab in Cachexia International Trial

NCT07112196Cancer-associated Cachexia

DrugsVisugromab·Visugromab RDE

CatalYm GmbH

Phase 2/3

518

A Coruña, Barcelona, Madrid, Majadahonda

2026-04-16

Recruiting

A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

NCT06769698Head and Neck Squamous Cell Carcinoma (HNSCC)

DrugCemiplimab

Regeneron Pharmaceuticals

Phase 2

120

Seville, Barcelona, A Coruña, Pamplona, Madrid, Zaragoza

2026-04-14

Recruiting

A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain

NCT07481630Obesity, Knee Osteoarthritis (OA)

DrugNNC0487-0111

Novo Nordisk A/S

Phase 3

400

A Coruña, Badalona, Ferrol, Madrid, Málaga, San Sebastián de Los Reyes (Madrid), Santander, Santiago de Compostela

2026-04-13

Recruiting

Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy

NCT07225270Ovarian Cancer, Platinum-sensitive Ovarian Cancer, PSOC

DrugsRina-S·Bevacizumab

Genmab

Phase 3

544

A Coruña

2026-04-03

Recruiting

Evaluation of Platelet-Rich Plasma (PRP) Treatment in Tendinopathies

NCT07558564Patellar Tendinopathy, Achilles Tendinopathy (AT), Epicondylitis, Lateral, Plantar Fasciitis, Chronic

DrugPlatelet rich plasma

ReSport Clinic

Observational

2,000

A Coruña, Barcelona, Madrid, Vitoria-Gasteiz

2026-04

Recruiting

A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis

NCT07067463Multiple Sclerosis (MS) Primary Progressive

DrugOrelabrutinib

Zenas BioPharma (USA), LLC

Phase 3

705

Vigo, Madrid, Majadahonda, Castilleja de la Cuesta, A Coruña

2026-03-23

Recruiting

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes

NCT07351058Obesity or Overweight, Type 2 Diabetes Mellitus

Hoffmann-La Roche

Phase 3

1,600

Badalona, A Coruña, Ferrol, Pozuelo de Alarcón, Barcelona, Madrid, Málaga, Seville

2026-03-23

Recruiting

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes

NCT07351045Obesity or Overweight

Hoffmann-La Roche

Phase 3

2,000

Santander, A Coruña, Pamplona, Barcelona, Madrid, Seville, Valencia

2026-03-16

Not yet open

Treatment for Ph-negative ALL for Adults up to 65 Years

NCT07443592Acute Lymphoblastic Leukemia

PETHEMA Foundation

Not applicable

330

A Coruña, Alava, Albacete, Alicante, Almería, Arrecife, Ávila, Badajoz

2026-03-06

Recruiting

Trastuzumab Deruxtecan in First-Line HER2-Positive Metastatic Breast Cancer With Proactive Toxicity Management

NCT07371585Breast Cancer Stage IV

DrugsPertuzumab·Trastuzumab deruxtecan

SOLTI Breast Cancer Research Group

Phase 2

300

Barcelona, A Coruña, Alicante, Badajoz, Bilbao, Girona, Granada, L'Hospitalet de Llobregat

2026-02-18

Recruiting

A Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Person Was Last Seen Well

NCT07361302Acute Ischemic Stroke

DrugTenecteplase

Boehringer Ingelheim

Phase 3

1,325

A Coruña, Alicante, Barakaldo, Barcelona, Girona, L'Hospitalet de Llobregat, Madrid, Salamanca

2026-02-17

Recruiting

A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)

NCT07318558Ovarian Neoplasms, Ovarian Cancer

DrugsMvasi·Sacituzumab tirumotecan·Avastin·Bevacizumab

Merck Sharp & Dohme LLC

Phase 3

900

Girona, A Coruña, Madrid, Valencia, Barcelona, Córdoba

2026-02-16

Recruiting

Real-life Experience of Brentuximab Vedotin Plus CHP as First-line Treatment of CD30+ Peripheral T-cell Lymphomas in Spain

NCT07624838CD30-Positive Peripheral T-Cell Lymphoma

DrugBrentuximab Vedotin

Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea

Observational

100

A Coruña, Palma de Mallorca, Badalona, Barcelona, L'Hospitalet de Llobregat, Sant Joan Despí, Santander, Jerez de la Frontera

2026-02-15

Recruiting

A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy

NCT07210723Symptomatic Genetic Dilated Cardiomyopathy

DrugDanicamtiv

Kardigan, Inc.

Phase 2/3

332

Horta-Guinardó, Majadahonda, A Coruña, Barcelona, Málaga, Murcia, Palma de Mallorca, Seville

2026-02-13

Recruiting

A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)

NCT07202546HIV Infections

DrugsVH4524184·Dovato·Dolutegravir/Lamivudine

ViiV Healthcare

Phase 2

186

A Coruña, Alicante, Almería, Badalona, Barcelona, Elche Alicante, Getafe, Granada

2026-02-11

Recruiting

A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin

NCT07392190Overweight, Obesity

DrugEloralintide

Eli Lilly and Company

Phase 3

900

A Coruña, Almería, Barcelona, Ferrol, Palma de Mallorca, Pozuelo de Alarcón, Santander, Seville

2026-02-10

Recruiting

Effectiveness of a Counseling Program on Exclusive Breastfeeding Rates in a Primary Care Center

NCT07309510Growth & Development, Breastfeeding Satisfaction, Breastfeeding Consultancy Training, Breastfeeding Duration

Fundación Pública Galega de Investigación Biomédica INIBIC

Not applicable

160

A Coruña

2026-02-01

Recruiting

Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer

NCT07288177Non-small Cell Lung Cancer (NSCLC)

DrugRina-S

Genmab

Phase 2

240

A Coruña, Barcelona, Las Palmas de Gran Canaria, Logroño, Madrid, Málaga, Pamplona, Valencia

2026-01-30

Recruiting

A Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants With Active Psoriatic Arthritis

NCT07321873Arthritis, Psoriatic

Janssen Research & Development, LLC

Phase 2

240

A Coruña, Santiago de Compostela, Seville

2026-01-15

Recruiting

A Clinical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemiplimab in Patients With Surgically Removed Non-small Cell Lung Cancer Who Have Not Received Prior Chemotherapy

NCT06931717Non-Small Cell Lung Cancer

DrugCemiplimab

ETOP IBCSG Partners Foundation

Phase 3

390

A Coruña, Alicante, Barakaldo, Barcelona, Granada, Jerez de la Frontera, Madrid, Santa Cruz de Tenerife

2026-01-12

By invitation

Lead Evaluation for Defibrillation and Reliability Post Approval Study

NCT07005232Tachyarrhythmia

Medtronic

Observational

2,000

Granada, A Coruña, Madrid, Santa Cruz de Tenerife, Valencia

2026-01-07

Recruiting

AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer

NCT07218809Epithelial Ovarian Cancer

DrugsTorvutatug samrotecan·MIRV·Mirvetuximab Soravtansine·Pegylated liposomal doxorubicin

AstraZeneca

Phase 3

1,100

A Coruña, Badalona, Barcelona, Córdoba, Donostia / San Sebastian, Girona, L'Hospitalet de Llobregat, Madrid

2025-12-29

Recruiting

NEXUS Study: A Study to Test Single and Multiple Doses of MER511 Given to Adults With Graves' Disease

NCT07305818Graves Disease

Merida Biosciences

Phase 1

100

A Coruña, Barcelona, Santander, Seville

2025-12-19

Active, closed

Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy

NCT07225686Obesity, Obstructive Sleep Apnea

DrugMaridebart cafraglutide

Amgen

Phase 3

250

Barcelona, A Coruña, Pozuelo de Alarcón, Madrid

2025-12-19

Recruiting

BaLloon-based PFA Ablation poST Approval Outcomes for PAF and PersAF

NCT07181590Paroxysmal AF, Atrial Arrhythmia, Atrial Fibrillation, Persistent Atrial Fibrillation

Abbott Medical Devices

Not applicable

300

A Coruña, Madrid, Valencia

2025-12-11

Recruiting

NOPE37: Angiogenic Factors for Managing Term Preeclampsia

NCT07193680Preeclampsia

Hospital Universitari Vall d'Hebron Research Institute

Not applicable

750

Barcelona, A Coruña, Alicante, Cabueñes, Cadiz, Elche, Getafe, Girona

2025-12-04

Recruiting

A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

NCT07213674Metastatic Castration-resistant Prostate Cancer

DrugsXaluritamig·Cabazitaxel·Abiraterone acetate·Docetaxel

Amgen

Phase 3

750

Málaga, Barcelona, L'Hospitalet de Llobregat, A Coruña, Lugo, Majadahonda, Pamplona, Madrid

2025-11-28

Recruiting

Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer

NCT07166094Endometrial Cancer, Recurrent or Progressive Endometrial Cancer

DrugRina-S

Genmab

Phase 3

660

Palma de Mallorca, Barcelona, Girona, A Coruña, Madrid, Málaga, Pamplona, Valencia

2025-11-28

Recruiting

A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer

NCT07155174Small Cell Lung Cancer

DrugsABBV-706·Lurbinectedin·Etoposide·Atezolizumab

AbbVie

Phase 2

180

Málaga, A Coruña, Barcelona, Madrid

2025-11-25

Active, closed

Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy

NCT07226765Obstructive Sleep Apnea

DrugMaridebart cafraglutide

Amgen

Phase 3

250

Barcelona, A Coruña, Pozuelo de Alarcón, Madrid

2025-11-25

Recruiting

A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

NCT07174310Parkinson's Disease

DrugPrasinezumab

Hoffmann-La Roche

Phase 3

900

Elche, Sant Cugat del Vallès, Donostia / San Sebastian, A Coruña, Alcorcón, Pozuelo de Alarcón, Barcelona, Madrid

2025-11-24

Recruiting

Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer

NCT07228832Metastatic Colorectal Cancer (CRC)

DrugsIvonescimab·Leucovorin·Adrucil·Oxaliplatin

Summit Therapeutics

Phase 3

600

A Coruña, Barcelona, Córdoba, Granada, Madrid, Málaga, Palma de Mallorca, Santander

2025-11-18

Recruiting

A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer

NCT07059845Ovarian Cancer

DrugsMirvetuximab Soravtansine·Bevacizumab·Carboplatin

AbbVie

Phase 2

400

Santander, Donostia / San Sebastian, Las Palmas de Gran Canaria, Majadahonda, Seville, A Coruña, Barcelona, Girona

2025-11-13

Recruiting

DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy

NCT07472517Small Cell Lung Cancer (SCLC), Extensive-stage Small Cell Lung Cancer (ES-SCLC)

DrugsObrixtamig·Etoposide·Atezolizumab·Carboplatin

Boehringer Ingelheim

Phase 3

670

A Coruña, Barcelona, Girona, L'Hospitalet de Llobregat, Las Palmas de Gran Canaria, Madrid, Málaga, Palma de Mallorca

2025-11-07

Recruiting

Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

NCT07291037Non-small Cell Lung Cancer (NSCLC)

DrugsDato-DXd·Docetaxel

AstraZeneca

Phase 3

400

A Coruña, Barcelona, L'Hospitalet de Llobregat, Madrid, Málaga, Seville, Zaragoza

2025-10-31

Recruiting

A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer

NCT07205822Breast Cancer

DrugDato-DXd

AstraZeneca

Phase 3

100

A Coruña, Barcelona, Granada, Madrid, Seville, Valencia

2025-10-30

Recruiting

Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer

NCT06899126Non-small Cell Lung Cancer

DrugsTrastuzumab deruxtecan·Pemetrexed·Keytruda·Pembrolizumab

Daiichi Sankyo

Phase 3

686

A Coruña, Barcelona, Burgos, Castellion, Las Palmas de Gran Canaria, Lugo, Madrid, Málaga

2025-10-24

Recruiting

A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

NCT07165028Metabolic Dysfunction-Associated Steatotic Liver Disease

DrugsRetatrutide·Tirzepatide

Eli Lilly and Company

Phase 3

4,500

A Coruña, Badalona, Barcelona, Ferrol, Huelva, Madrid, Palma, Pontevedra

2025-10-15

Recruiting

EPIK-P4: A Phase II Single-arm Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS)

NCT06997588PIK3CA-related Overgrowth Spectrum (PROS)

DrugAlpelisib

Novartis Pharmaceuticals

Phase 2

140

Esplugues, A Coruña, Barcelona, Madrid

2025-10-09

Recruiting

A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

NCT07190248Non-small Cell Lung Cancer

Drugs) Berahyaluronidase alfa·Calderasib·Paraplatin·Pemetrexed

Merck Sharp & Dohme LLC

Phase 3

675

Badalona, Barcelona, A Coruña, Majadahonda, Valencia, Madrid, Seville

2025-10-08

Recruiting

A Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy

NCT07023614Non-obstructive Hypertrophic Cardiomyopathy

Imbria Pharmaceuticals, Inc.

Phase 2

165

Barcelona, A Coruña, Madrid, Vigo, Seville, El Palmar, Palma de Mallorca, Salamanca

2025-10-06

Recruiting

CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis

NCT07207811Transthyretin Amyloid Cardiomyopathy (ATTR CM)

DrugNNC6019-0001

Novo Nordisk A/S

Phase 3

1,280

A Coruña, Badalona, Barcelona, Bilbao, Córdoba, Donostia / San Sebastian, L'Hospitalet de Llobregat, Las Palmas de Gran Canaria

2025-10-02

Recruiting

Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer

NCT07022483Endometrial Cancer

DrugTrastuzumab deruxtecan

Daiichi Sankyo

Phase 3

710

A Coruña, El Palmar, Madrid, Palma de Mallorca

2025-09-30

Recruiting

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

NCT07144280Non-small Cell Carcinoma, Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Carcinoma

DrugsPF-08046054·Docetaxel

Pfizer

Phase 3

680

A Coruña, Badalona, Barcelona, Madrid, Badajoz, Granada, Palma, Seville

2025-09-29

Recruiting

Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease

NCT07181109High Risk Cardiovascular Disease, Hypertension, High Cardiovascular Risk

DrugZilebesiran

Alnylam Pharmaceuticals

Phase 3

11,000

A Coruña, Alcalá de Henares, Alicante, Antequera, Badajoz, Barcelona, Burjassot, Cadiz

2025-09-22

Active, closed

Durvalumab After Chemoradiotherapy in Limited Stage Small Cell Lung Cancer.

NCT06992609Small Cell Lung Carcinoma

DrugDurvalumab

AstraZeneca

Phase 3

A Coruña, Badajoz, Barakaldo, Barcelona, Madrid, Málaga, Oviedo, Santander

2025-09-15

Active, closed

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee

NCT07153471Osteoarthritis

DrugOrforglipron

Eli Lilly and Company

Phase 3

800

A Coruña, Barcelona, Málaga, Santander, Santiago de Compostela, Seville, Valladolid

2025-09-15

Recruiting

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

NCT06926868Breast Neoplasms

DrugsIza-bren·Nab-paclitaxel·Capecitabine·Gemcitabine

Bristol-Myers Squibb

Phase 2/3

600

A Coruña, Elche, Barcelona, Hospitalet, Donostia / San Sebastian, Madrid, Málaga, Valencia

2025-09-11

Recruiting

A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer

NCT06919965Non-Muscle Invasive Bladder Neoplasms

DrugsErdafitinib·Mitomycin C·Gemcitabine

Janssen Research & Development, LLC

Phase 3

220

A Coruña, Barcelona, Cadiz, Castellon, Ferrol, Jerez de la Frontera, Madrid, Málaga

2025-09-10

Recruiting

A Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in Spain

NCT07029737Mantle-cell Lymphoma

DrugsLisaftoclax·Acalabrutinib

AstraZeneca

Phase 2

A Coruña, Alcorcón, Badalona, Barcelona, Burgos, Donostia / San Sebastian, Gijón, Madrid

2025-09-05

Recruiting

Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)

NCT07157774Elevated Lp(a), Atherosclerotic Cardiovascular Disease (ASCVD)

Eli Lilly and Company

Phase 3

10,450

A Coruña, Barcelona, Centelles, Córdoba, Ferrol, Granada, Huelva, Jaén

2025-09-02

Recruiting

Medical Device for Sustained Remission in Rheumatoid Arthritis Treated With Biological Therapy

NCT07678112Rheumatoid Arthritis (RA)

Francisco J. Blanco

Not applicable

184

A Coruña, Alava, Barcelona, Madrid, Málaga, San Cristóbal de La Laguna

2025-08-28

Active, closed

A Study of SPY072 in Rheumatic Disease

NCT07148414Rheumatoid Arthritis, Psoriatic Arthritis, Axial Spondyloarthritis, Rheumatic Diseases

DrugSPY072

Spyre Therapeutics, Inc.

Phase 2

285

A Coruña, Chiclana de la Frontera, Santander, Seville

2025-08-21

Active, closed

A Study to Compare Different Doses of RO7795081 With Placebo or Semaglutide in People With Type 2 Diabetes

NCT07112872Type 2 Diabetes Mellitus

DrugsRO7795081·Semaglutide

Hoffmann-La Roche

Phase 2

330

Seville, Santander, Castilleja de la Cuesta, A Coruña, Ferrol, Malaga, Málaga, Barcelona

2025-08-19

Recruiting

A Study Investigating Intravenous Human Normal Immunoglobulin 10% in Adults With Chronic Immune Thrombocytopenia (ITP)

NCT07059000Chronic Primary Immune Thrombocytopenia (ITP)

DrugKedrion IVIG

Kedrion S.p.A.

Phase 3

Burgos, A Coruña, Madrid

2025-08-13

Recruiting

A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)

NCT06979596Malignant Neoplasm

DrugsOpevesostat·Tamoxifen·Exemestane·Letrozole

Merck Sharp & Dohme LLC

Phase 2

250

L'Hospitalet de Llobregat, A Coruña, Madrid

2025-08-11

Recruiting

A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)

NCT07098338Non-Small Cell Lung Cancer

DrugsRamucirumab·Rilvegostomig·Dato-DXd

AstraZeneca

Phase 2

278

A Coruña, Madrid, Manresa, Málaga, Santander, Valencia

2025-08-07

Active, closed

A Study Evaluating Persistence of the Immune Response of the Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine and the Safety and Immune Response Following Revaccination in Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant

NCT07092865Respiratory Syncytial Virus Infections

GlaxoSmithKline

Phase 2

168

A Coruña, Barcelona, Córdoba, Madrid, Santander

2025-08-06

Recruiting

A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer

NCT06774131Upper Urinary Tract Urothelial Carcinoma, Urothelial Carcinoma

UroGen Pharma Ltd.

Phase 3

Barcelona, A Coruña, Madrid, Cadiz, Córdoba, Murcia, Seville, Valencia

2025-08-06

Recruiting

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

NCT07062965Breast Cancer

DrugsPrifetrastat·Exemestane·Everolimus·Fulvestrant

Pfizer

Phase 3

400

A Coruña, Barcelona, Bilbao, Málaga, Granada, Jaén, Zaragoza

2025-08-05

Recruiting

A Study of Dotinurad Versus Allopurinol in Participants With Gout

NCT07089875Gout

DrugsDotinurad·Allopurinol

Crystalys Therapeutics

Phase 3

500

A Coruña, Santiago de Compostela, Alcobendas, Madrid, Seville, Barcelona

2025-08-01

Recruiting

A Study With CIT-013 in RA Patients

NCT06567470Rheumatoid Arthritis

DrugsCIT-013 medium·CIT-013

Citryll BV

Phase 2

A Coruña, Barcelona, Madrid, Santander, Santiago de Compostela

2025-07-29

Recruiting

A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis

NCT07071519Ulcerative Colitis

DrugRisankizumab

AbbVie

Phase 3

120

A Coruña, Majadahonda

2025-07-28

Recruiting

Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

NCT06757634Breast Cancer

DrugsGedatolisib·Ribociclib·Palbociclib·Letrozole

Celcuity Inc

Phase 3

1,180

A Coruña, Badajoz, Barcelona, Cáceres, El Palmar, L'Hospitalet de Llobregat, Lleida, Madrid

2025-07-24

Recruiting

Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke

NCT05691244Acute Ischemic Stroke, Cerebral Stroke

DrugSovateltide

Pharmazz, Inc.

Phase 3

514

Badalona, Barcelona, Albacete, Madrid, El Palmar, Seville, Tarragona, A Coruña

2025-07-24

Recruiting

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

NCT06758401Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)

DrugsSigvotatug vedotin·Pembrolizumab

Pfizer

Phase 3

714

A Coruña, Elche, Barcelona, L'Hospitalet de Llobregat, Jerez de la Frontera, Palma, Madrid, Valencia

2025-07-23

Recruiting

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

NCT07060807Breast Neoplasms

DrugsPatritumab deruxtecan·Pegylated liposomal doxorubicin·Abraxane·Xeloda

Merck Sharp & Dohme LLC

Phase 3

1,000

Badalona, Santander, A Coruña, Barcelona, Madrid, Seville

2025-07-21

Active, closed

Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer

NCT06933329Non-Small Cell Lung Cancer

DrugZelenectide pevedotin

BicycleTx Limited

Phase 2

A Coruña, Madrid

2025-07-18

Recruiting

Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC

NCT06765109Non-small Cell Lung Cancer, Anaplastic Lymphoma Kinase-positive

DrugsNeladalkib·Alectinib

Nuvalent Inc.

Phase 3

450

A Coruña, Badalona, Barcelona, Girona, Madrid, Málaga, Seville

2025-07-17

Recruiting

A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised

NCT07013474COVID-19 Infection

DrugsIbuzatrelvir·Veklury·Remdesivir

Pfizer

Phase 3

300

A Coruña, Córdoba, Badalona, Barcelona, Madrid, Vigo, Alicante, Seville

2025-07-14

Recruiting

A Phase 1b/2a Trial to Evaluate Invobenitug Also Known as Procizumab (PCZ; AK1967) in Critical Cardiovascular Care.

NCT06832722Shock, Cardiogenic

4TEEN4 Pharmaceuticals GmbH

Phase 1/2

A Coruña, Barcelona, Madrid

2025-07-13

Recruiting

A Phase 1b Study of Budoprutug in Systemic Lupus Erythematosus (SLE)

NCT07011043Systemic Lupus Erythematosus

DrugBudoprutug

Climb Bio, Inc.

Phase 1

Sabadell, A Coruña

2025-07-10

Recruiting

Neoadjuvant Treatment With Atezolizumab and Atezolizumab as Maintenance for the Treatment of Stage III Non Small-Cell Lung Cancer (NSCLC)

NCT07153445Non Small Cell Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer

DrugsTecentriq·Paraplatin·Taxol·Atezolizumab

Fundación GECP

Phase 2

Alicante, Badalona, Barcelona, Bilbao, Jerez de la Frontera, Girona, Granada, A Coruña

2025-07-08

Recruiting

TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

NCT07052903Transthyretin Amyloidosis With Cardiomyopathy

DrugNucresiran

Alnylam Pharmaceuticals

Phase 3

1,750

A Coruña, Barcelona, Bilbao, El Palmar, Huelva, Jaén, L'Hospitalet de Llobregat, Lleida

2025-07-02

Recruiting

Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

NCT07037459Heart Failure With Preserved Ejection Fraction, Heart Failure With Mildly Reduced Ejection Fraction, Obesity

DrugMaridebart cafraglutide

Amgen

Phase 3

5,056

Córdoba, Málaga, Las Palmas de Gran Canaria, Badalona, Barcelona, L'Hospitalet de Llobregat, Lleida, A Coruña

2025-06-25

Recruiting

A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis

NCT06972446Rheumatoid Arthritis

DrugsABBV-8736·ABBV-701·Lutikizumab·Adalimumab

AbbVie

Phase 2

180

Sabadell, Seville, Bilbao, A Coruña, Córdoba, Madrid, Valencia

2025-06-20

Recruiting

Study of Cetuximab Plus/Minus Weekly Paclitaxel After Progression To First-Line Pembrolizumab Plus Platinum-5FU in Subjects With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck.

NCT06856213Recurrent / Metastatic Head and Neck Squamous Cell Carcinoma

DrugsCetuximab·Paclitaxel

Grupo Español de Tratamiento de Tumores de Cabeza y Cuello

Phase 2

Santiago de Compostela, Badalona, Barcelona, Santander, Granada, A Coruña, Lugo, Madrid

2025-06-18

Active, closed

A Trial to Investigate the Safety and Efficacy of Intra-articular 4P004 Injection in Subjects With Knee Synovitis and Osteoarthritis

NCT07225829Knee Osteoarthritis, Synovitis of Knee

DrugLiraglutide

4Moving Biotech

Phase 2

129

A Coruña, Alicante, Sabadell, Santiago de Compostela, Seville

2025-06-17

Recruiting

A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation (The ReInspire Study)

NCT06789913PIK3CA-Related Overgrowth Spectrum (PROS), Lymphatic Malformations, Vascular Malformations, PIK3CA Mutation

DrugRLY-2608

Relay Therapeutics, Inc.

Phase 2

277

A Coruña, Barcelona, Madrid

2025-06-13

Active, closed

PLUG-IN: Pembrolizumab Combined With Enfortumab Vedotin for Advanced Melanoma Patients

NCT06906822Melanoma

DrugsEnfortumab Vedotin·Pembrolizumab

Grupo Español Multidisciplinar de Melanoma

Phase 2

A Coruña, Badalona, Barcelona, Santander, Madrid, Murcia, Seville, Valencia

2025-06-10

Active, closed

A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With HeFH

NCT07000136Heterozygous Familial Hypercholesterolaemia

DrugAZD0780

AstraZeneca

Phase 3

473

A Coruña, Barcelona, Córdoba, Reus, Seville

2025-06-10

Recruiting

The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis

NCT06872892Bronchiectasis

DrugVerducatib

Boehringer Ingelheim

Phase 3

1,755

A Coruña, Badalona, Barcelona, El Palmar, Girona, Huelva, Jerez de la Frontera, L'Hospitalet de Llobregat

2025-06-09

Recruiting

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

NCT06852222Leukemia, Myeloid, Acute

DrugsBleximenib·Azacitidine·Venetoclax

Janssen Research & Development, LLC

Phase 3

600

A Coruña, Barcelona, Cáceres, Jerez de la Frontera, L'Hospitalet de Llobregat, Madrid, Pamplona, Pozuelo de Alarcón

2025-06-04

Recruiting

A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event

NCT07000357Cardiovascular Disease

DrugAZD0780

AstraZeneca

Phase 3

15,100

A Coruña, Alicante, Barcelona, Cáceres, Huelva, Madrid, Málaga, Murcia

2025-06-04

Recruiting

Encorafenib and biNimetinib Followed by CEmiplimab and FiAnLimab in Patients With BRAF Mutant melanOma and Symptomatic Brain Metastases

NCT06887088Melanoma BRAF V600E/K Mutated, Melanoma and Brain Metastases

DrugsFianlimab·Binimetinib·Encorafenib·Cemiplimab

Grupo Español Multidisciplinar de Melanoma

Phase 2

A Coruña, Barcelona, Burgos, Santander, Cáceres, Donostia / San Sebastian, Madrid, Majadahonda

2025-05-29

Active, closed

A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event

NCT07000123Cardiovascular Disease

DrugAZD0780

AstraZeneca

Phase 3

3,103

A Coruña, Barcelona, Córdoba, Madrid, Santiago(A Coruña), Seville

2025-05-28

Recruiting

A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer

NCT06901531Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma

DrugsZolbetuximab·Adrucil·Capecitabine·Oxaliplatin

Astellas Pharma Global Development, Inc.

Phase 3

500

Elche, San Cugat Del Valles Barcelona, Madrid, Navarra, A Coruña, Barcelona, El Palmar, Lleida

2025-05-22

Active, closed

Long-term Study Evaluating Joint Health in People With Haemophilia A Receiving Real-world Prophylactic Treatment With Efanesoctocog Alfa

NCT06940830Hemophilia A

DrugEfanesoctocog alfa

Swedish Orphan Biovitrum

Phase 4

252

Salamanca, A Coruña, Barcelona, Málaga, Palma de Mallorca, Zaragoza

2025-05-21

Recruiting

Optimizing Reperfusion to Improve Outcomes and Neurologic Function

NCT06990867Acute Ischemic Stroke

Corxel Pharmaceuticals

Phase 2/3

740

A Coruña, Albacete, Barcelona, Girona, Madrid, Málaga, Seville, Valencia

2025-05-15

Active, closed

Study of GS-0151 in Participants With Rheumatoid Arthritis

NCT06902519Rheumatoid Arthritis

Gilead Sciences

Phase 1

A Coruña, Barcelona, Madrid, Sabadell, Seville

2025-05-14

Recruiting

Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant

NCT06563895Amyloidosis, Amyloid Cardiomyopathy, Transthyretin Amyloidosis, Cardiomyopathies

DrugAcoramidis

Eidos Therapeutics, a BridgeBio company

Phase 3

587

A Coruña, Barcelona, Huelva, Majadahonda, Palma de Mallorca, Salamanca

2025-05-12

Recruiting

FB-CT2 Includes Two Prospective, Multi-centre Studies With a Medical Device in Hospital Settings: a Randomized, Dual-arm, Open-label Pilot Study in Spain, Followed by a Single-arm, Non-randomized, Open-label International Pivotal Study

NCT06968364Threatened Preterm Labor

Ultrasound-Innovation Medtech, S.L.

Not applicable

457

A Coruña, Barcelona, Bilbao, Donostia / San Sebastian, Granada, Las Palmas de Gran Canaria, Madrid, Málaga

2025-05-10

Recruiting

A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)

NCT06935357Immunoglobulin A Nephropathy (IgAN)

DrugFelzartamab

Biogen

Phase 3

454

Viladecans, Barcelona, A Coruña, Alcorcón, Getafe, Cáceres, Girona, Madrid

2025-05-08

Recruiting

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

NCT06881784NSCLC (Non-small Cell Lung Cancer), Non-Small Cell Lung Cancer, NSCLC, NSCLC (Non-small Cell Lung Carcinoma)

DrugsCetuximab·Docetaxel

Revolution Medicines, Inc.

Phase 3

590

A Coruña, Barcelona, Fuencarral-El Pardo, Madrid

2025-05-06

Recruiting

VitaFlow LIBERTY Europe

NCT06535659Aortic Valve Stenosis

Shanghai MicroPort CardioFlow Medtech Co., Ltd.

Observational

222

A Coruña, Madrid, Valladolid

2025-05-06

Active, closed

A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidity

NCT06965413Obesity, Overweight, Overweight With One Weight Related Comorbidity

DrugsRO7204239·Tirzepatide

Hoffmann-La Roche

Phase 2

285

Seville, Santander, Castilleja de la Cuesta, A Coruña, Barcelona, Málaga

2025-05-05

Active, closed

A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1

NCT06948435Hypertension, Overweight or Obesity

DrugOrforglipron

Eli Lilly and Company

Phase 3

487

A Coruña, Barcelona, Centelles, León, Seville

2025-04-30

Active, closed

Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD

NCT06813911Atherosclerotic Cardiovascular Disease (ASCVD)

DrugsPelacarsen·Inclisiran

Novartis Pharmaceuticals

Phase 3

246

Santiago Compostela, Pamplona, Castilleja de la Cuesta, A Coruña, Barcelona, Córdoba, Huelva, Las Palmas GC

2025-04-30

Active, closed

A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)

NCT06948422Hypertension

DrugOrforglipron

Eli Lilly and Company

Phase 3

974

A Coruña, Barcelona, Centelles, León, Seville

2025-04-30

Active, closed

A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2

NCT06952530Hypertension

DrugOrforglipron

Eli Lilly and Company

Phase 3

487

A Coruña, Barcelona, Centelles, León, Seville

2025-04-30

Active, closed

A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight

NCT06914895Type 1 Diabetes, Obesity, Overweight

DrugTirzepatide

Eli Lilly and Company

Phase 3

905

A Coruña, Barcelona, Ferrol, Móstoles, Santander, Seville

2025-04-25

Recruiting

A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

NCT06875310Carcinoma, Non-Small-Cell Lung

DrugsAdagrasib·Pemetrexed·Keytruda·Cisplatin

Mirati Therapeutics Inc.

Phase 3

630

A Coruña, Santiago de Compostela, Barcelona, Hospitalet, Palma, Madrid, Majadahonda, Pontevedra

2025-04-24

Recruiting

Effect of Partially Hydrolyzed Formula With Synbiotics on Skin Barrier Function

NCT06943469Atopic Dermatitis (AD)

Société des Produits Nestlé (SPN)

Not applicable

400

A Coruña, Almería, Barcelona, Madrid, Málaga, Seville, Tarragona, Zaragoza

2025-04-10

Active, closed

Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia

NCT06822790Hypertriglyceridemia

DrugPlozasiran

Arrowhead Pharmaceuticals

Phase 3

710

A Coruña, Barcelona, Madrid, Santiago de Compostela, Seville, Valencia, Zaragoza

2025-04-09

Recruiting

Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer

NCT06801834Extensive Stage Small Cell Lung Cancer (ES-SCLC)

DrugsAmrubicin·Lurbinectedin·Topotecan·Sacituzumab Govitecan

Gilead Sciences

Phase 3

695

A Coruña, Barcelona, Girona, Jaén, Las Palmas de Gran Canaria, Madrid, Málaga, Seville

2025-04-04

Not yet open

Effectiveness of Therapeutic Exercise Combined With Respiratory Muscle Training in Patients With Subacute Stroke

NCT06949839Stroke

Ana Lista Paz

Not applicable

A Coruña

2025-04

Recruiting

Real-World Study to Assess Subcutaneous Epcoritamab in Adult Participants With Diffuse Large B-Cell and Follicular Lymphoma

NCT06830759Diffuse Large B-cell Lymphoma, Follicular Lymphoma

AbbVie

Observational

700

A Coruña, Badalona, Sabadell, Córdoba, Marbella, Pamplona, Seville, Manises

2025-03-28

Recruiting

DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

NCT06989112Endometrial Cancer

DrugsRilvegostomig·Taxotere·Paraplatin·Trastuzumab deruxtecan

AstraZeneca

Phase 3

600

A Coruña, Córdoba, Donostia / San Sebastian, El Palmar, L'Hospitalet de Llobregat, Madrid, Palma de Mallorca, Valencia

2025-03-27

Recruiting

Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)

NCT06819007Ovarian Cancer

DrugsTrastuzumab deruxtecan·Bevacizumab

Daiichi Sankyo

Phase 3

582

A Coruña, Barcelona, Córdoba, El Palmar, Madrid, Palma, Pamplona, Planta Baja

2025-03-19

Recruiting

Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin

NCT06677060Heart Failure

DrugBaxdrostat/dapagliflozin

AstraZeneca

Phase 3

11,300

A Coruña, Barcelona, Córdoba, L'Hospitalet de Llobregat, Madrid, Málaga, Sant Joan Despí, Santiago(A Coruña)

2025-03-14

Recruiting

Safety and Efficacy of Intravenous Thrombolysis in Patients With Ischemic Stroke and Direct Oral Anticoagulants Intake

NCT06571149Ischemic Stroke

DrugsAlteplase·Tenecteplase

Insel Gruppe AG, University Hospital Bern

Phase 4

906

A Coruña, Barcelona, Girona, Madrid, Seville, Valladolid, Zaragoza

2025-03-14

Active, closed

Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight

NCT06858839Obesity

DrugMaridebart cafraglutide

Amgen

Phase 3

3,853

Almería, Castilleja de la Cuesta, Huelva, Sanlúcar de Barrameda, Seville, A Coruña, Pozuelo de Alarcón, Pamplona

2025-03-12

Recruiting

Alleviant ALLAY-HFrEF Study

NCT06812533Heart Failure

Alleviant Medical, Inc.

Not applicable

350

A Coruña, Barcelona, Madrid, Salamanca, Valencia

2025-03-10

Recruiting

Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations

NCT06772623Non Small Cell Lung Carcinoma, c-MET

DrugsBudigalimab·Telisotuzumab Adizutecan·Pemetrexed·Cisplatin

AbbVie

Phase 1/2

252

Santander, Seville, A Coruña, Alicante, Barcelona, Málaga

2025-03-06

Recruiting

Study to Provide Continued Access to Treatment for Patients Completing a Previous Trial With Efanesoctocog Alfa

NCT06716814Haemophilia A (Moderate or Severe)

DrugEfanesoctocog alfa

Swedish Orphan Biovitrum

Phase 3

104

A Coruña, Zaragoza

2025-03-06

Recruiting

A Study of Mocertatug Rezetecan in Combination With Anti-cancer Therapies for Advanced Solid Tumors (BEHOLD-2)

NCT06796907Tumours, Gynecological

DrugsMo-Rez·Dostarlimab·Bevacizumab

GlaxoSmithKline

Phase 1/2

305

A Coruña, Barcelona, Madrid, Málaga, Valencia, Zaragoza

2025-03-04

Recruiting

A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure

NCT06742723Chronic Kidney Disease and Hypertension

DrugBaxdrostat/dapagliflozin

AstraZeneca

Phase 3

5,000

A Coruña, Almería, Badalona, L'Hospitalet de Llobregat, Majadahonda, Málaga, Palma deMallorca, Pamplona

2025-03-03

Active, closed

A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC

NCT06745323Small Cell Lung Cancer (SCLC)

DrugTarlatamab

Amgen

Phase 2

252

Las Palmas de Gran Canaria, Barcelona, A Coruña, Madrid

2025-02-26

Active, closed

A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic Arthritis

NCT06878404Arthritis, Psoriatic

DrugIcotrokinra

Janssen Research & Development, LLC

Phase 3

552

A Coruña, Barcelona, Córdoba, Madrid, Málaga, Sabadell, Santander, Seville

2025-02-21

Active, closed

Observational Study to Evaluate Fertility in Women Between 32 and 38 Years Old Treated With the Ovosicare® Fertility

NCT07083999Fertility

Procare Health Iberia S.L.

Observational

300

Sitges, Getafe, Benalmádena, Estella-Lizarra, A Coruña, Alicante, Almería, Barcelona

2025-02-13

Active, closed

Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer

NCT06619236Platinum-resistant Ovarian Cancer

DrugsRina-S·Pegylated liposomal doxorubicin·Topotecan·Gemcitabine

Genmab

Phase 3

584

A Coruña, Donostia / San Sebastian, El Palmar, Madrid, Seville, Valencia, Zaragoza

2025-02-07

Recruiting

Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free.

NCT06431633Lung Diseases, Carcinoma, Non-Small-Cell Lung, Resectable Lung Non-Small Cell Carcinoma

DrugsZimberelimab·Sacituzumab Govitecan·Paraplatin·Cisplatin

Fundación GECP

Phase 3

129

Alicante, Elche, Badalona, Barcelona, L'Hospitalet de Llobregat, Bilbao, Jerez de la Frontera, A Coruña

2025-02-04

Active, closed

A Safety and Tolerability Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)

NCT06812325Thyroid Eye Disease (TED)

DrugVRDN-003

Viridian Therapeutics, Inc.

Phase 3

320

A Coruña, Barcelona, Córdoba, Madrid, Navarrés, Seville, Zaragoza

2025-02-03

Recruiting

Endoscopy/Robotic Assisted Nipple Skin Sparing Mastectomy

NCT06823414Breast Cancer Early Stage Breast Cancer (Stage 1-3), Breast Cancer Non-invasive Breast Cancer, High Risk Breast Carcinoma

Alejandra García-Novoa

Observational

126

A Coruña

2025-02-01

Recruiting

Follow-up of Spanish Prospective Asthma and Nasal Polyposis Registry

NCT06163807Chronic Asthma

Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz

Observational

1,200

Santiago de Compostela, Badalona, Barcelona, A Coruña, Madrid, Pamplona

2025-02-01

Active, closed

A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjögren's Syndrome

NCT06684847Primary Sjogrens Disease

DrugEfgartigimod PH20

argenx

Phase 3

631

Vitoria-Gasteiz, Badajoz, Barcelona, Santiago de Compostela, Madrid, A Coruña, Seville, Valencia

2025-01-15

Recruiting

A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis

NCT06807424Arthritis, Psoriatic

DrugIcotrokinra

Janssen Research & Development, LLC

Phase 3

750

A Coruña, Córdoba, L'Hospitalet de Llobregat, Madrid, Málaga, Santander, Santiago de Compostela, Seville

2025-01-09

Active, closed

Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis

NCT06846541Plaque Psoriasis, Psoriasis (PsO), Psoriasis, Moderate Psoriasis

Alumis Inc

Phase 3

1,680

Alicante, Barcelona, Madrid, A Coruña, Manises

2025-01-08

Recruiting

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer

NCT06712316Non-small Cell Lung Cancer

DrugsPumitamig·Pemetrexed·Paclitaxel·Carboplatin

BioNTech SE

Phase 2/3

1,580

A Coruña, Badajoz, Badalona, Barcelona, Castellon, Las Palmas de Gran Canaria, León, Lleida

2025-01-07

Active, closed

Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease

NCT06760637Breast Cancer

DrugsAtirmociclib·Abemaciclib·Ribociclib·Palbociclib

Pfizer

Phase 3

1,035

A Coruña, Elche, Seville, Barcelona, L'Hospitalet de Llobregat, Eixample, Bilbao, Jerez de la Frontera

2025-01-06

Active, closed

A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01)

NCT06660654Advanced Solid Tumor, Metastatic Solid Tumors

DrugR-DXd

Daiichi Sankyo

Phase 2

335

A Coruña, Barcelona, Madrid, Málaga

2025-01-06

By invitation

Effectiveness of Home-Based Exercise and Brain Stimulation for Reducing Fatigue in Patients With Multiple Sclerosis

NCT07567989Multiple Sclerosis

Jacobo Formigo

Not applicable

A Coruña, Santiago de Compostela, Vigo

2025-01-01

Active, closed

A Study to Evaluate the Use of Durvalumab in Combination With Platinum-based Chemotherapy Followed by Durvalumab With Olaparib as First-line Treatment in Advanced or Recurrent Endometrial Cancer in Spain

NCT06746116Advanced or Recurrent Endometrial Cancer

DrugDurvalumab

AstraZeneca

Phase 3

A Coruña, Alicante, Barakaldo, Barcelona, Córdoba, El Palmar, Girona, L'Hospitalet de Llobregat

2024-12-30

Active, closed

A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell Lung Cancer (BENITO Study)

NCT06687369Non Squamous Non Small Cell Lung Cancer

DrugsEU sourced Keytruda·US-sourced Keytruda·Pemetrexed·Cisplatin

mAbxience Research S.L.

Phase 3

726

A Coruña, Barcelona, Madrid, Málaga, Murcia, Oviedo, Palma de Mallorca, Pontevedra

2024-12-30

Recruiting

Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction

NCT06736574Heart Failure, Heart Failure With Reduced Ejection Fraction

Cytokinetics

Phase 3

1,800

A Coruña, Santiago de Compostela, Barcelona, L'Hospitalet de Llobregat, Úbeda, Lugo, Madrid, Majadahonda

2024-12-19

Recruiting

A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease

NCT06679140COVID-19 SARS-CoV-2 Infection

DrugIbuzatrelvir

Pfizer

Phase 3

2,330

A Coruña, Benalmádena, Córdoba, Badalona, Barcelona, Madrid, Vigo, Alicante

2024-12-08

Recruiting

Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.

NCT06382948Advanced Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer, ESR1 Gene Mutation

DrugsElacestrant·Everolimus

MedSIR

Phase 3

300

Barcelona, A Coruña, Alicante, Badalona, Bilbao, Burgos, Castellon, Cáceres

2024-12-05

Recruiting

Niraparib Rechallenge After Surgery in Ovarian Cancer Patients With Oligometastatic Progression

NCT06180356Ovarian Cancer, Oligometastatic Disease, Serous Ovarian Tumor

DrugNiraparib

MedSIR

Phase 2

A Coruña, Barakaldo, Barcelona, Girona, Jaén, Madrid, Málaga, Oviedo

2024-12-03

Recruiting

Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor

NCT06472245Patients With Non-Small Cell Lung Cancer

DrugsTedopi·Docetaxel

OSE Immunotherapeutics

Phase 3

363

Palma de Mallorca, Badalona, L'Hospitalet de Llobregat, Barakaldo, A Coruña, Las Palmas de Gran Canaria, Majadahonda, Marbella

2024-12-03

Recruiting

Validation of the MaiRa Preeclampsia Test for Screening Early/Late Preeclampsia in First and Second Trimesters

NCT06716242Preeclampsia (PE)

iPremom

Observational

7,473

Alicante, Barcelona, Vinaròs, Cadiz, A Coruña, Torrejón de Ardoz, El Palmar, San Cristóbal de La Laguna

2024-12-02

Recruiting

A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)

NCT06667700Coronavirus Disease (COVID-19)

DrugMolnupiravir

Merck Sharp & Dohme LLC

Phase 3

3,082

Elche, Badalona, Centelles, Barcelona, A Coruña, Cartagena, Madrid, Seville

2024-12-02

Recruiting

A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus

NCT06617325Systemic Lupus Erythematosus

UCB Biopharma SRL

Phase 3

450

A Coruña, Badajoz, Barcelona, Castellon, Madrid, Málaga, Mérida, Sabadell

2024-11-21

Recruiting

Study to Evaluate the Efficacy of Axicabtagene Ciloleucel in Patients With Late Relapse of Diffuse Large B-Cell Lymphoma

NCT07254754DIFFUSE LARGE B-CELL LYMPHOMA

DrugAxicabtagene Ciloleucel

Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea

Phase 2

A Coruña, Palma de Mallorca, Santander, Salamanca, Barcelona, L'Hospitalet de Llobregat, San Sebastián, Las Palmas de Gran Canaria

2024-11-20

Recruiting

LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

NCT06632457Metabolic Dysfunction Associated Steatohepatitis

Boehringer Ingelheim

Phase 3

1,590

A Coruña, Barcelona, Córdoba, Madrid, Majadahonda, Pontevedra, Santiago de Compostela

2024-11-12

Active, closed

A Study of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus (T2DM)

NCT06660173Type 2 Diabetes Mellitus (T2DM)

DrugMaridebart cafraglutide

Amgen

Phase 2

409

Castilleja de la Cuesta, Málaga, Lleida, A Coruña, Alzira

2024-11-07

Recruiting

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

NCT06623422Carcinoma, Non-Small-Cell Lung

DrugsIntismeran autogene·Paraplatin·Taxol·Pemetrexed

Merck Sharp & Dohme LLC

Phase 3

680

Canarias, A Coruña, Pozuelo de Alarcón, Barcelona, Madrid, Málaga

2024-10-21

Recruiting

A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia

NCT06544499Primary Immune Thrombocytopenia (ITP)

DrugEfgartigimod

argenx

Phase 3

A Coruña, L'Hospitalet de Llobregat, Madrid, Murcia, Pozuelo de Alarcón, Valencia

2024-10-18

Active, closed

Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response

NCT06641089Arthritis, Psoriatic

DrugsSonelokimab·Risankizumab

MoonLake Immunotherapeutics AG

Phase 3

600

A Coruña, Alcobendas, Bilbao, Castellon, Madrid, Málaga, Sabadell, Santiago de Compostela

2024-10-15

Active, closed

Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug

NCT06641076Arthritis, Psoriatic

DrugSonelokimab

MoonLake Immunotherapeutics AG

Phase 3

960

A Coruña, Alcobendas, Bilbao, Castelló, Madrid, Málaga, Sabadell, Santiago de Compostela

2024-10-15

Recruiting

LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

NCT06632444Metabolic Dysfunction Associated Steatohepatitis (MASH), Liver Fibrosis

Boehringer Ingelheim

Phase 3

1,800

A Coruña, Barcelona, Córdoba, Madrid, Majadahonda, Pontevedra, Santander, Santiago de Compostela

2024-10-14

Recruiting

Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations

NCT06581432Solid Tumours

DrugZongertinib

Boehringer Ingelheim

Phase 2

588

A Coruña, Badalona, Barcelona, Madrid, Pamplona, Seville, Valencia

2024-10-11

Recruiting

Safety and Effectiveness of Short-Term Single AntiPlatelet Therapy After Left Atrial Appendage Closure With the LAmbre Device in Patients With Nonvalvular Atrial Fibrillation: A Multinational Real-world Registry

NCT06620757Atrial Fibrillation

Fundación EPIC

Observational

234

A Coruña, Aravaca, Barcelona, Córdoba, Fuencarral-El Pardo, Gijón, L'Hospitalet de Llobregat, Las Palmas de Gran Canaria

2024-10-10

Active, closed

Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1

NCT06630286HIV-1-infection

DrugsISL/LEN·B/F/TAF

Gilead Sciences

Phase 3

609

A Coruña, Barcelona, Málaga

2024-10-09

Recruiting

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

NCT06561386Non-small Cell Lung Cancer

DrugsRelatlimab·Pemetrexed·Nivolumab·Cisplatin

Bristol-Myers Squibb

Phase 3

1,000

A Coruña, Barcelona, L'Hospitalet de Llobregat, Palma, Madrid, Majadahonda, Valencia, Málaga

2024-10-07

Recruiting

A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

NCT06417814Metastatic Non-small Cell Lung Cancer

DrugsTagrisso·Dato-DXd·Osimertinib·Pemetrexed

AstraZeneca

Phase 3

744

A Coruña, Barakaldo, Barcelona, El Palmar, L'Hospitalet de Llobregat, Madrid, Majadahonda, Málaga

2024-10-04

Recruiting

Study of Antitumor Immune Response After cCRT and IO Treatment in Non-resectable III Stage NSCLC Patients

NCT06634199Non-small Cell Lung Cancer Stage III, PDL1 Gene Mutation

DrugDurvalumab

Fundación GECP

Observational

Ferrol, Alicante, Badalona, Barcelona, Bilbao, Ciudad Real, Girona, A Coruña

2024-10-03

Recruiting

A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer

NCT06545955Non-muscle Invasive Bladder Cancer With Carcinoma in Situ

DrugsNadofaragene Firadenovec·Docetaxel·Gemcitabine·Pembrolizumab

Ferring Pharmaceuticals

Phase 3

250

Santander, Barcelona, Córdoba, A Coruña, Alcorcón, Madrid, Pamplona, Bilbao

2024-10-01

Recruiting

Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer

NCT06510374Intermediate Risk Non-Muscle Invasive Bladder Cancer

DrugNadofaragene Firadenovec

Ferring Pharmaceuticals

Phase 3

454

Santander, Barcelona, Córdoba, A Coruña, Granada, Alcorcón, Madrid, Bilbao

2024-10-01

Recruiting

Multicenter Trial of Proximal Femoral Guided Growth in Children With CP and Hips at Risk of Dislocation (GGSH-MC)

NCT06956729Cerebral Palsy

Fundación para la investigación biomética Hospital Infantil Universitario Niño Jesús

Not applicable

A Coruña, Almería, Seville, Palma, Salamanca, Barcelona, Donostia / San Sebastian, Madrid

2024-10-01

Recruiting

RESTI Registry: Spanish Registry of Primary Immune Thrombocytopenia and Other Immune Thrombocytopenia

NCT06919341ITP - Immune Thrombocytopenia, Primary Immune Thrombocytopenia (ITP)

Fundación Española de Hematología y Hemoterapía

Observational

1,000

A Coruña, Palma, Barcelona, Terrassa, Bilbao, Torrelavega, Castellon, Algeciras

2024-09-27

Active, closed

Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)

NCT06430866Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC)

DrugsABP 234·Pembrolizumab

Amgen

Phase 3

163

A Coruna Galicia, A Coruña, Alicante, Badalona, Barcelona, Jerez de la Frontera, Madrid, Mataró

2024-09-12

Recruiting

A Phase II Study of Ensifentrine in Non-Cystic Fibrosis Bronchiectasis

NCT06559150Non-cystic Fibrosis Bronchiectasis

Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA

Phase 2

284

A Coruña, Barcelona, Madrid

2024-09-11

Recruiting

A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B

NCT06379789Hemophilia B

Regeneron Pharmaceuticals

Phase 1/2

130

Seville, A Coruña, El Palmar, Oviedo, Barcelona, Madrid, Valencia, Zaragoza

2024-09-11

Recruiting

Prospective Observational Study to Evaluate the Safety of Immunotherapy as a Treatment for Hymenoptera Venom Allergy

NCT06782217Allergy, Insect Venom, Allergy Insect Stinging, Insect Sting Allergy

DrugVenox

Inmunotek S.L.

Observational

120

Ferrol, Plasencia, Burela de Cabo, Monforte de Lemos, A Coruña, Barcelona, Lugo, Ourense

2024-09-01

Recruiting

CRS Questionnaire Validation Project

NCT06970977Chronic Rhinosinusitis (CRS) With and Without Nasal Polyps

The European Forum for Research and Education in Allergy and Airway Diseases

Observational

1,000

A Coruña, Barcelona, Cadiz, Madrid, Ponferrada, Santander, Seville, Valencia

2024-09-01

Recruiting

A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

NCT06452277Advanced Non-small Cell Lung Cancer, HER2 Mutation

DrugsSevabertinib·Pemetrexed·Cisplatin·Carboplatin

Bayer

Phase 3

555

Badalona, Majadahonda, Pamplona, A Coruña, Barcelona, Madrid, Valencia

2024-08-28

Active, closed

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)

NCT06486441Endometrial Cancer

DrugsAdriamycin·Sacituzumab Govitecan·Taxol·Doxorubicin

Gilead Sciences

Phase 3

640

A Coruña, Barcelona, Jaén, Madrid, Málaga, Palma, Sabadell, San Sebastián

2024-08-28

Active, closed

Volrustomig Priming Regimens Exploratory Phase II Platform Study

NCT06448754Non-small Cell Lung Cancer

DrugsVolrustomig·Ramucirumab·Pemetrexed·Paclitaxel

AstraZeneca

Phase 2

194

A Coruña, Alcorcón, Barcelona, Madrid, Málaga, Pamplona, Santander, Santiago de Compostela

2024-08-27

Recruiting

A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients With Heart Failure Who Are Intolerant or Not Eligible for Treatment With Steroidal Mineralocorticoid Receptor Antagonists

NCT06033950Heart Failure

DrugFinerenone

Colorado Prevention Center

Phase 3

2,600

Girona, A Coruña, Santiago de Compostela, Madrid, Majadahonda, Málaga, Manises, Valencia

2024-08-20

Recruiting

A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer

NCT06435429Metastatic HER2-positive Breast Cancer

DrugsZanidatamab·Eribulin·Vinorelbine·Trastuzumab

Jazz Pharmaceuticals

Phase 3

550

A Coruña, Badajoz, Barcelona, Elche, Granada, Madrid, San Cristóbal de La Laguna, Seville

2024-08-13

Active, closed

Open-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef Extension

NCT06492291Hypercholesterolemia

DrugsEnlicitide·Enlicitide Decanoate

Merck Sharp & Dohme LLC

Phase 3

3,000

Málaga, Centelles, Barcelona, Figueres, A Coruña, Santiago de Compostela, Pozuelo de Alarcón, Alcorcón

2024-08-05

Recruiting

Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

NCT06380751Advanced Breast Cancer

DrugsSaruparib·Camizestrant·Exemestane·Anastrozole

AstraZeneca

Phase 3

788

A Coruña, Barcelona, Cáceres, Granada, L'Hospitalet de Llobregat, Madrid, Málaga, Pamplona

2024-08-01

Active, closed

A Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 to Slow Progression of Progressive Supranuclear Palsy (PSP)

NCT06355531Progressive Supranuclear Palsy

Ferrer Internacional S.A.

Phase 2

241

A Coruña, Badalona, Barakaldo, Barcelona, Madrid, Pamplona, Seville, Valencia

2024-07-23

Recruiting

A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF)

NCT06024746Heart Failure

DrugsFinerenone·Dapagliflozin

Colorado Prevention Center

Phase 3

1,500

A Coruña, Santiago de Compostela, Madrid, Málaga, Manises, Valencia, Barcelona

2024-07-09

Active, closed

Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL PFS with1mL Pre-filled Syringe in Adult Participants With Autoimmune Disease

NCT06293365Sjögrens Disease, Systemic Lupus Erythematosus, Rheumatoid Arthritis

DrugIanalumab

Novartis Pharmaceuticals

Phase 2

155

Santiago Compostela, A Coruña, Madrid

2024-07-02

Recruiting

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

NCT06324357Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma

DrugsZongertinib·Zanidatamab·Trastuzumab emtansine·MFOLFOX6

Boehringer Ingelheim

Phase 1/2

768

A Coruña, Barcelona, L'Hospitalet de Llobregat, Madrid, Seville, Valencia

2024-06-28

Active, closed

Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR)

NCT06331312Polymyalgia Rheumatica

DrugSecukinumab

Novartis Pharmaceuticals

Phase 3

162

Sabadell, Bilbao, A Coruña, Madrid, Seville, Valencia

2024-06-28

Active, closed

ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack

NCT06118281Cardiovascular Risk, Acute Myocardial Infarction (AMI)

DrugZiltivekimab

Novo Nordisk A/S

Phase 3

10,000

Badalona, Málaga, El Palmar, A Coruña, Alicante, Barcelona, Lleida, Madrid

2024-06-25

Recruiting

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

NCT06393374Triple-Negative Breast Cancer

DrugsXeloda·Sacituzumab tirumotecan·Keytruda·Capecitabine

Merck Sharp & Dohme LLC

Phase 3

1,530

Seville, L'Hospitalet de Llobregat, A Coruña, Madrid, Majadahonda, Valencia, Barcelona

2024-06-24

Recruiting

A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)

NCT06455449Polymyositis, Dermatomyositis

AstraZeneca

Phase 3

240

A Coruña, Barcelona, Córdoba, L'Hospitalet de Llobregat, Madrid, Sabadell, Valladolid

2024-06-20

Active, closed

Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma

NCT06356129Large B-cell Lymphoma

DrugsGolcadomide·Vincristine·Doxorubicin·Prednisone

Celgene

Phase 3

850

A Coruña, Badalona, L'Hospitalet Del Llobregat, Barakaldo, Santa Cruz de Tenerife, Donostia / San Sebastian, Majadahonda, El Palmar, Murcia

2024-06-19

Active, closed

A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)

NCT06472076Lung Cancer, Non-Small Cell

DrugsBelrestotug·Dostarlimab·Pembrolizumab

GlaxoSmithKline

Phase 3

A Coruña, Aravaca, BaracaldoVizcaya, Barcelona, Jaén, Las Palmas de Gran Canar, Madrid, Oviedo

2024-06-10

Recruiting

Wereables for Upper Limb Functionality in Hemiparesis

NCT06872736Unilateral Cerebral Palsy

Universidade da Coruña

Phase 2/3

A Coruña

2024-06-07

Active, closed

Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

NCT06082167Head and Neck Squamous Cell Carcinoma

DrugsZanzalintinib·Keytruda·Pembrolizumab

Exelixis

Phase 2/3

600

A Coruña, Barcelona, Girona, Madrid, Pamplona, Seville, Valencia, Zaragoza

2024-06-07

Recruiting

IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)

NCT06112314Advanced Melanoma

DrugsBrenetafusp·Relatlimab·Opdivo·Nivolumab

Immunocore Ltd

Phase 3

680

Santander, El Palmar, A Coruña, Barcelona, Córdoba, Granada, Las Palmas de Gran Canaria, Madrid

2024-06-05

Recruiting

A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

NCT06430801Crohn's Disease

DrugTulisokibart

Merck Sharp & Dohme LLC

Phase 3

1,200

Badalona, Barcelona, A Coruña, Majadahonda, Torrejón de Ardoz, Madrid, Pontevedra, Santa Cruz de Tenerife

2024-06-05

Not yet open

Management of Early-onset Fetal Growth Restriction: Angiogenic Factors Versus Feto-placental Doppler

NCT05284474Fetal Growth Retardation, Preeclampsia, Placenta Diseases

Hospital Universitari Vall d'Hebron Research Institute

Not applicable

340

A Coruña, Alicante, Badalona, Barcelona, Cadiz, Elche, Getafe, Gijón

2024-06-03

Active, closed

A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).

NCT06412666Pediatric, Symptomatic Obstructive Hypertrophic Cardiomyopathy

DrugAficamten

Cytokinetics

Phase 2/3

A Coruña, Barcelona

2024-05-29

Recruiting

MYTHS-MR Trial (MYocarditis THerapy With Steroids in Patients With Mildly Reduced Ejection Fraction)

NCT05974462Acute Myocarditis

DrugsSolu-Medrol·Methylprednisolone

University Hospital, Antwerp

Phase 3

174

A Coruña

2024-05-24

Recruiting

VE303 for Prevention of Recurrent Clostridioides Difficile Infection

NCT06237452Clostridium Difficile, Clostridium Difficile Infections, Clostridium Difficile Infection Recurrence, Clostridioides Difficile Infection

Vedanta Biosciences, Inc.

Phase 3

852

Badalona, Barcelona, Terrassa, San Sebastián, Madrid, Majadahonda, Seville, A Coruña

2024-05-20

Active, closed

INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC

NCT06295731Head and Neck Squamous Cell Carcinoma (HNSCC)

DrugsKeytruda·Pembrolizumab

Inhibrx Biosciences, Inc

Phase 2/3

410

Santiago, Barcelona, Pamplona, Madrid, A Coruña, Valencia

2024-05-14

Active, closed

A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)

NCT06356311Gastroesophageal Cancer

DrugsTrifluridine/Tipiracil·Sacituzumab tirumotecan·Irinotecan·Docetaxel

Merck Sharp & Dohme LLC

Phase 3

450

Santander, A Coruña, Pamplona, Oviedo, Barcelona, Madrid

2024-05-03

Recruiting

Hyperangulated vs Macintosh Blades for Intubation With Videolaryngoscopy in ICU

NCT06322719Acute Respiratory Failure, Intubation, Intubation; Difficult or Failed, Videolaryngoscopy

Hospital Clinico Universitario de Santiago

Not applicable

1,036

Santiago de Compostela, A Coruña, Albacete, Barcelona, Cáceres, Denia, Elche, Gijón

2024-05-01

Active, closed

The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

NCT06383390Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)

DrugRetatrutide

Eli Lilly and Company

Phase 3

10,000

A Coruña, Almería, Alzira, Barcelona, Ferrol, Málaga, Oviedo, Palma de Mallorca

2024-04-30

Recruiting

Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer

NCT06350097Non-small Cell Lung Cancer

DrugsDato-DXd·Osimertinib

AstraZeneca

Phase 3

582

A Coruña, Barcelona, Granada, Madrid, Majadahonda, Valencia

2024-04-29

Recruiting

Reduction of the Incidence of NAV in Neonatal Units (INBERNAV-Neo)

NCT07240038Pneumonia Ventilator Associated, Pneumonia Neonatal, Healthcare-associated Infections

Biobizkaia Health Research Institute

Observational

1,500

A Coruña, Santiago de Compostela, Albacete, Badalona, Barcelona, Barakaldo, Bilbao, Burgos

2024-04-26

Recruiting

A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer

NCT06319820Non-Muscle Invasive Bladder Neoplasms

DrugGemcitabine

Janssen Research & Development, LLC

Phase 3

641

A Coruña, Alzira, Barcelona, Cadiz, Castellon, Jerez de la Frontera, Madrid, Málaga

2024-04-18

Active, closed

A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.

NCT06372145Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis

DrugTeriflunomide

Sanofi

Phase 3

2,500

A Coruña, Seville, Barcelona, L'Hospitalet de Llobregat, Barakaldo, Santiago de Compostela, Donostia / San Sebastian, Salt

2024-04-16

Active, closed

A Study of Barzolvolimab in Patients With Prurigo Nodularis

NCT06366750Prurigo Nodularis

DrugBarzolvolimab

Celldex Therapeutics

Phase 2

140

A Coruña, Alicante, Barcelona, Madrid, Seville

2024-04-12

Recruiting

Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function

NCT06307652Heart Failure and Impaired Kidney Function

AstraZeneca

Phase 3

3,850

A Coruña, Barcelona, Lugo, Madrid, Majadahonda, Seville, Valencia

2024-04-12

Active, closed

A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom State

NCT06245408Sjögren's Syndrome (SS)

DrugDazodalibep

Amgen

Phase 3

434

Córdoba, Bilbao, A Coruña, Madrid, San Cristóbal de La Laguna, Santa Coloma de Gramenet(Barcelona), Seville, Vitoria-Gasteiz

2024-04-08

Active, closed

A PoC Study to Evaluate Treatments' Efficacy by Monitoring MRD Using ctDNA in HR-positive/HER2-negative EBC Population

NCT05708235Breast Cancer

DrugsGiredestrant·Inavolisib·Abemaciclib

MedSIR

Phase 2

976

A Coruña, Alicante, Barcelona, Bilbao, Castellon, Córdoba, Elche, Girona

2024-04-01

Active, closed

Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)

NCT06291376Immunoglobulin A Nephropathy, IgAN

DrugRavulizumab

Alexion Pharmaceuticals, Inc.

Phase 3

584

A Coruña, Alcalá de Henares, Lleida, Madrid, Málaga, Murcia, Oviedo, Seville

2024-03-29

Active, closed

A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.

NCT06268873Chronic Kidney Disease and Hypertension

DrugBaxdrostat/dapagliflozin

AstraZeneca

Phase 3

2,554

A Coruña, Almería, Badalona, L'Hospitalet de Llobregat, Lugo, Madrid, Málaga, Palma deMallorca

2024-03-29

Recruiting

Reduced Stent Strategy Versus Conventional Percutaneous Coronary Revascularization in Patients Presenting With STEMI

NCT06353594ST Elevation Myocardial Infarction

Hospital Universitario La Fe

Not applicable

1,272

Huelva, Valencia, A Coruña, Burgos, Castelló, Córdoba, Elche, Granada

2024-03-11

Active, closed

A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

NCT06292013Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)

DrugLepodisiran

Eli Lilly and Company

Phase 3

17,300

A Coruña, Alcorcón, Badalona, Barcelona, Córdoba, Denia, El Palmar, Murcia, Ferrol

2024-03-05

Active, closed

A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer

NCT06012435Carcinoma, Non-Small-Cell Lung

DrugsSigvotatug vedotin·Docetaxel

Seagen, a wholly owned subsidiary of Pfizer

Phase 3

762

Palma, A Coruña, Barcelona, Alicante, Badalona, Castellon, Madrid, Málaga

2024-02-21

Active, closed

Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib

NCT06120140Carcinoma, Non-Small-Cell Lung

DrugsClobetasol·Minocycline·Chlorhexidine·Clindamycin

Janssen Research & Development, LLC

Phase 2

305

A Coruña, Alicante, Barcelona, Jaén, Lugo, Madrid, Málaga, Seville

2024-02-16

Active, closed

Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

NCT06151574Lung Cancer, Non-squamous, Non-small Cell

DrugsZongertinib·Pemetrexed·Keytruda·Cisplatin

Boehringer Ingelheim

Phase 3

428

A Coruña, Alicante, Barcelona, Bilbao, Madrid, Málaga, Seville, Valencia

2024-02-09

Recruiting

Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

NCT06162221Non-Small Cell Lung Cancer, NSCLC, KRAS, NRAS, HRAS-mutated NSCLC, KRAS G12C-mutated Solid Tumors, Lung Cancer, Lung Cancer Stage IV, Advanced Solid Tumor, Cancer

DrugsElironrasib·RMC-9805·Cetuximab·Pemetrexed

Revolution Medicines, Inc.

Phase 1/2

616

Madrid, Pamplona, Valencia, A Coruña, Barcelona, Málaga, Seville

2024-01-18

Recruiting

A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients

NCT06008197Heart Failure, Acute Heart Failure

DrugsKerendia·Finerenone

Colorado Prevention Center

Phase 3

5,200

Villamartín, Zaragoza, Badalona, Sanlúcar de Barrameda, A Coruña, Santiago de Compostela, Pamplona, Barcelona

2024-01-17

Active, closed

A Study to Compare the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Pembrolizumab (SB27, EU Sourced Keytruda, and US Sourced Keytruda) in Subjects With Stage II-IIIA NSCLC Following Complete Resection and Adjuvant Platinum-based Chemotherapy

NCT06268613Non-small Cell Lung Cancer Stage II, Non-small Cell Lung Cancer Stage IIIA

DrugsEU sourced Keytruda·US-sourced Keytruda·Pembrolizumab

Samsung Bioepis Co., Ltd.

Phase 1

163

Jaén, A Coruña, Málaga

2024-01-16

Recruiting

Prospective, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Endovascular Treatment in Patients With Cerebral Aneurysms Using P64 and P48 Flow-Diverter Stents

NCT06201598Cerebral Aneurysm, Thromboembolic Disease

Hospital Universitario Central de Asturias

Observational

100

A Coruña, Badalona, Barcelona, Burgos, Donostia / San Sebastian, Madrid, Málaga, Oviedo

2024-01-12

Active, closed

Study of ALXN2220 Versus Placebo in Adults With ATTR-CM

NCT06183931Transthyretin Amyloid Cardiomyopathy

DrugCliramitug

Alexion Pharmaceuticals, Inc.

Phase 3

1,181

A Coruña, Barcelona, El Palmar, Jaén, L'Hospitalet de Llobregat, Madrid, Majadahonda, Málaga

2024-01-11

Recruiting

Use of Mesenchymal Stem Cells in Pre-term Patients With Bronchopulmonary Dysplasia.

NCT06270199Bronchopulmonary Dysplasia

Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal

Phase 2

Pozuelo de Alarcón, A Coruña, Madrid, Málaga, Seville, Valencia

2024-01-11

Recruiting

A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)

NCT06174987Advanced Cancer, Metastatic Cancer

DrugTrastuzumab deruxtecan

Daiichi Sankyo

Phase 3

A Coruña, Barcelona, Distrito de Les Corts, L'Hospitalet de Llobregat, Madrid

2024-01-05

Recruiting

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

NCT06119581Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

DrugsOlomorasib·Pemetrexed·Cisplatin·Carboplatin

Eli Lilly and Company

Phase 3

1,264

A Coruña, Badajoz, Barakaldo, Barcelona, Hospitalet, Jerez de la Frontera, Las Palmas de Gran Canaria, León

2023-12-21

Active, closed

A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)

NCT06140836Carcinoma, Non-Small-Cell Lung

DrugsRepotrectinib·Crizotinib

Bristol-Myers Squibb

Phase 3

190

A Coruña, Santiago de Compostela, Barcelona, Madrid, Majadahonda, Málaga, Seville, Valencia

2023-12-21

Recruiting

Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLC

NCT05718323SCLC,Extensive Stage, SLFN11-positive

DrugNiraparib

ETOP IBCSG Partners Foundation

Phase 2

A Coruña, Jaén, Madrid

2023-12-20

Recruiting

A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

NCT06136650Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostatic Neoplasms

DrugsFludrocortisone acetate·Opevesostat·Prednisone Acetate·Zytiga

Merck Sharp & Dohme LLC

Phase 3

1,314

Sabadell, Barcelona, Girona, A Coruña, Las Palmas de Gran Canaria, Pozuelo de Alarcón, Burgos, Málaga

2023-12-18

Active, closed

REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)

NCT05973773Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation

DrugZipalertinib

Taiho Oncology, Inc.

Phase 3

285

Barcelona, A Coruña, Madrid, Málaga, Jaén

2023-12-18

Recruiting

Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

NCT06170788Non-small Cell Lung Cancer (NSCLC)

DrugsSacituzumab tirumotecan·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 3

614

Jerez de la Frontera, A Coruña, Pozuelo de Alarcón, Málaga, Valencia, Barcelona, Madrid, Santa Cruz de Tenerife

2023-12-15

Recruiting

A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma

NCT06091865Diffuse Large B-cell Lymphoma (DLBCL)

DrugsOdronextamab·Prednisone/Prednisolone·Adriamycin·Cytoxan

Regeneron Pharmaceuticals

Phase 3

904

Santiago de Compostela, Seville, Palma, Badalona, Sabadell, Terrassa, Santander, A Coruña

2023-12-13

Recruiting

MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)

NCT06128629Transthyretin Amyloidosis (ATTR) With Cardiomyopathy

DrugNexiguran ziclumeran

Intellia Therapeutics

Phase 3

1,200

A Coruña, Barcelona, Majadahonda, Málaga, Palma de Mallorca

2023-12-13

Recruiting

A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma

NCT06091254Follicular Lymphoma (FL)

DrugsOdronextamab·Prednisone/Prednisolone·Adriamycin·Bendamustine

Regeneron Pharmaceuticals

Phase 3

822

Santiago de Compostela, Málaga, Seville, Palma, Barakaldo, Santander, A Coruña, Pozuelo de Alarcón

2023-12-12

Recruiting

Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.

NCT05948943Lymphatic Malformations

DrugAlpelisib

Novartis Pharmaceuticals

Phase 2/3

232

Palma, Esplugues, L'Hospitalet de Llobregat, A Coruña, Barcelona, Madrid

2023-11-24

Recruiting

Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)

NCT06095583Limited-stage Small Cell Lung Cancer (LS-SCLC)

DrugsTifcemalimab·Toripalimab

Shanghai Junshi Bioscience Co., Ltd.

Phase 3

756

A Coruña, Barcelona, Jaén, Madrid, San Sebastián, Zaragoza

2023-11-15

Active, closed

Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)

NCT05925803Systemic Sclerosis, Scleroderma

AstraZeneca

Phase 3

314

A Coruña, Barcelona, Madrid, Málaga, Valencia

2023-11-08

Active, closed

A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome.

NCT05985915Sjogrens Syndrome

DrugIanalumab

Novartis Pharmaceuticals

Phase 3

612

Badalona, Sabadell, Bilbao, Santander, Vigo, A Coruña, Barcelona, Córdoba

2023-10-27

Recruiting

A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma

NCT06084936Lymphoma

DrugsGlofitamab·Bendamustine·Tocilizumab·Obinutuzumab

Hoffmann-La Roche

Phase 3

182

Cadiz, A Coruña, Barcelona, Murcia

2023-10-22

Active, closed

Ischemic and Bleeding Outcomes After Angiolite Stent Implantation and an Abbreviated Dual Antiplatelet Therapy

NCT05952206Coronary Artery Disease

Drug12-month DAPT

iVascular S.L.U.

Phase 3

2,312

A Coruña, Almería, Barcelona, Cáceres, Huelva, Jerez de la Frontera, Las Palmas de Gran Canaria, León

2023-10-13

Recruiting

A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft Dysfunction

NCT06082037Lung Transplant Rejection

DrugsBelumosudil·Azithromycin

Sanofi

Phase 3

180

Santander, Barcelona, A Coruña, Majadahonda, Valencia

2023-10-10

Active, closed

An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

NCT05952557Breast Cancer, Early Breast Cancer

DrugsCamizestrant·Tamoxifen·Exemestane·Anastrozole

AstraZeneca

Phase 3

5,511

A Coruña, Albacete, Alicante, Badalona, Barakaldo, Barcelona, Burgos, Castellon

2023-10-05

Active, closed

Safety and Performance of REGENERA Breast Implant in Women Affected by Malignant Breast Lesion Treated by Lumpectomy

NCT05941299Mastectomy, Segmental, Breast Neoplasm Malignant Female

Tensive SRL

Not applicable

A Coruña

2023-09-29

Recruiting

Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)

NCT06079671Locally Advanced Cervical Cancer

DrugVolrustomig

AstraZeneca

Phase 3

800

A Coruña, Barcelona, Córdoba, Girona, Hospitalet deLlobregat, Madrid, Palma de Mallorca, Valencia

2023-09-22

Active, closed

Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)

NCT06088290Leiomyosarcoma

DrugsLurbinectedin·Doxorubicin

PharmaMar

Phase 3

469

A Coruña, Barcelona, Madrid, San Cristóbal de La Laguna, Seville, Valencia, Zaragoza

2023-09-21

Active, closed

A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's Syndrome

NCT05946941Sjögren's Syndrome

DrugDeucravacitinib

Bristol-Myers Squibb

Phase 3

774

Mérida, Santander, San Cristóbal de La Laguna, A Coruña, Santiago de Compostela, Seville

2023-09-11

Recruiting

A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer

NCT05894239Metastatic Breast Cancer

DrugsPhesgo·Inavolisib

Hoffmann-La Roche

Phase 3

230

A Coruña, Barcelona, Madrid, Málaga, Seville

2023-09-08

Recruiting

Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis

NCT06051617Primary Biliary Cholangitis

DrugSeladelpar

Gilead Sciences

Phase 3

402

A Coruña, Alcorcón, Badalona, Barcelona, Córdoba, Málaga, Santander, Seville

2023-09-07

Recruiting

Study of Personalized Allocation of Defibrillators in Non-ischemic Heart Failure (SPANISH-1)

NCT06055504Non-ischemic Dilated Cardiomyopathy

Consorcio Centro de Investigación Biomédica en Red (CIBER)

Not applicable

900

Santiago de Compostela, L'Hospitalet de Llobregat, Sabadell, A Coruña, Majadahonda, Oviedo, Alicante, Barcelona

2023-09-06

Active, closed

Enlighten Study: The EV-ICD Post Approval Registry

NCT06048731Ventricular Arrhythmia, Tachycardia

Medtronic

Observational

1,000

A Coruña, Barcelona, Córdoba, Girona, Granada, Valencia

2023-09-01

Active, closed

A Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)

NCT06081894Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy

DrugAficamten

Cytokinetics

Phase 3

500

A Coruña, Barcelona, Madrid, Málaga, Murcia, Palma de Mallorca, Salamanca, Seville

2023-08-31

Recruiting

OverTTuRe: Characteristics, Treatment Patterns and Outcomes of Patients With ATTR Amyloidosis

NCT06355934ATTR Amyloidosis

AstraZeneca

Observational

52,121

A Coruña, Barcelona, Bilbao, El Palmar, Huelva, Las Palmas de Gran Canaria, Madrid, Majadahonda

2023-08-21

Recruiting

Coroflex® ISAR NEO PMCF Study

NCT05698732Coronary Artery Disease (CAD), Ischemic Heart Disease

Fundación EPIC

Observational

3,000

A Coruña, Badajoz, Badalona, Barakaldo, Barcelona, Cáceres, Ciudad Real, Huelva

2023-08-04

Recruiting

OSIREAL - Osimertinib RWE on EGFRm NSCLC in Spain

NCT06068049Non-small Cell Lung Cancer

AstraZeneca

Observational

500

A Coruña, Alicante, Barcelona, C Rdoba, El Palmar, Girona, Granada, Jaén

2023-07-28

Active, closed

Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus

NCT05843643Systemic Lupus Erythematosus

DrugUpadacitinib

AbbVie

Phase 3

1,014

A Coruña, Vigo, Seville

2023-07-25

Recruiting

Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer

NCT05797831Endometrial Cancer

DrugNavtemadlin

Kartos Therapeutics, Inc.

Phase 2/3

268

A Coruña, Barcelona, Galdakao, Jaén, Jerez de la Frontera, Las Palmas, León, Santiago de Compostela

2023-07-17

Active, closed

Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus Erythematosus

NCT05966480SLE

DrugEnvudeucitinib

Alumis Inc

Phase 2

408

A Coruña, Alicante, Barcelona, Seville, Valencia

2023-06-26

Active, closed

Adagrasib in Patients With KRASG12C-mutant NSCLC Who Are Elderly or Have Poor Performance Status

NCT05673187NSCLC Stage IV, KRAS P.G12C

DrugAdagrasib

ETOP IBCSG Partners Foundation

Phase 2

A Coruña, Alicante, Badalona, Bilbao, L'Hospitalet de Llobregat, Madrid, Valencia

2023-06-12

Active, closed

Evaluation of the Safety and Efficacy of Eneboparatide (AZP-3601) in Patients With Chronic Hypoparathyroidism

NCT05778071Chronic Hypoparathyroidism, Endocrine System Diseases, Parathyroid Diseases

Alexion Pharmaceuticals, Inc.

Phase 3

165

A Coruña, Barcelona, Pamplona, Seville

2023-06-07

Active, closed

A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

NCT05869903Obesity, Overweight, Overweight or Obesity

DrugOrforglipron

Eli Lilly and Company

Phase 3

3,127

A Coruña, Ferrol, Almería, Málaga, Seville, Badalona, Barcelona, Valladolid

2023-06-05

Active, closed

Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)

NCT05607550Metastatic Non-Small Cell Lung Cancer, Advanced Non-Small Cell Lung Cancer, EGFR Exon 20 Mutations

DrugFurmonertinib

ArriVent BioPharma, Inc.

Phase 3

398

Málaga, A Coruña, Barcelona, Madrid, Valencia

2023-06-01

Active, closed

Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer

NCT05740566Small Cell Lung Cancer (SCLC)

DrugsAmrubicin·Lurbinectedin·Tarlatamab·Topotecan

Amgen

Phase 3

509

Málaga, Zaragoza, Barcelona, A Coruña, Majadahonda, Madrid

2023-05-31

Recruiting

Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)

NCT05714085Heart Failure, Left Ventricular Systolic Dysfunction

DrugVericiguat

Merck Sharp & Dohme LLC

Phase 2/3

342

Esplugues de Llobregat, Barcelona, A Coruña, Madrid, Seville

2023-05-31

Active, closed

PIK3CA/PTEN-altered Advanced Breast Cancer Treated With MEN1611 Monotherapy or in Combination With Eribulin

NCT05810870Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer

DrugEribulin

MedSIR

Phase 2

Granada, Seville, Donostia / San Sebastian, Santander, A Coruña, Torrejón de Ardoz, Vigo, Barcelona

2023-05-24

Recruiting

SUPRAFLEX CRUZ PMCF Study ( rEpic05 )

NCT05617599Coronary Artery Disease (CAD), Ischemic Heart Disease

Fundación EPIC

Observational

508

Elche, A Coruña, Barakaldo, Barcelona, Castelló, Cáceres, Ciudad Real, Girona

2023-05-10

Active, closed

Phase III Study of AK112 for NSCLC Patients

NCT06396065Non-Squamous Non-small Cell Lung Cancer

DrugsIvonescimab·Pemetrexed·Carboplatin

Summit Therapeutics

Phase 3

420

A Coruña, Barcelona, Las Palmas, Lugo, Madrid, Majadahonda, Málaga, Seville

2023-05-04

Active, closed

An Early Access Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma

NCT05876754Cholangiocarcinoma

DrugIvosidenib

Servier Affaires Médicales

Phase 3

299

A Coruña, Barcelona, Córdoba, Elche, Madrid, Pamplona, Santander

2023-05-03

Active, closed

A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation

NCT05757869Atrial Fibrillation

DrugsMilvexian·Apixaban

Janssen Research & Development, LLC

Phase 3

20,284

A Coruña, Alicante, Barcelona, El Palmar, Lleida, Madrid, Manises, Málaga

2023-04-11

Recruiting

AI-powered ECG Analysis Using Willem™ Software in High-risk Cardiac Patients (WILLEM)

NCT05890716Cardiomyopathies, Cardiac Arrest, Cardiac Arrhythmias, Sudden Cardiac Death

Idoven 1903 S.L.

Observational

5,342

Barcelona, Ciudad Real, A Coruña, Madrid, Murcia, Pamplona, Santa Cruz de Tenerife, Valencia

2023-04-04

Active, closed

Evaluation of the Viability and Safety of Early Discharge Protocol After TAVI Implantation

NCT05758909Aortic Valve Disease, Aortic Valve Stenosis, Heart Valve Diseases

Fundación EPIC

Observational

585

A Coruña, Alicante, Aravaca, Badalona, Barcelona, L'Hospitalet de Llobregat, Málaga, Oviedo

2023-04-04

Recruiting

A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy

NCT05774951Breast Cancer, Early Breast Cancer

DrugsCamizestrant·Tamoxifen·Exemestane·Anastrozole

AstraZeneca

Phase 3

4,300

A Coruña, Albacete, Alcoy, Alicante, Alzira, Badajoz, Badalona, Barakaldo

2023-03-31

Active, closed

Amivantamab, Lazertinib and Bevacizumab in Patients With EGFR-mutant Advanced Non-small Cell Lung Cancer With Progression on Previous Third-generation EGFR-TKI

NCT05601973Non Small Cell Lung Cancer

DrugsLazertinib·Zirabev·Amivantamab

ETOP IBCSG Partners Foundation

Phase 2

A Coruña, Alicante, Badalona, Barcelona, Bilbao, L'Hospitalet de Llobregat, Madrid, Valladolid

2023-03-27

Active, closed

A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)

NCT05714202Bladder Cancer

DrugsTAR-200·Cetrelimab

Janssen Research & Development, LLC

Phase 3

1,135

A Coruña, Algeciras, Barcelona, Cadiz, Castellon, L'Hospitalet de Llobregat, Lugo, Madrid

2023-03-23

Active, closed

Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer

NCT05445778Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer

DrugsMirvetuximab Soravtansine·Bevacizumab

AbbVie

Phase 3

520

A Coruña, L'Hospitalet de Llobregat, Córdoba, Málaga, Pamplona, Barcelona, Girona, Madrid

2023-03-15

Recruiting

Erdafitinib Monotherapy or in Combination With Cetrelimab in Muscle-invasive Bladder Cancer Patients With Fibroblast Growth Factor Receptor (FGFR ) Gene Alterations

NCT06511648Muscle-invasive Bladder Cancer

DrugErdafitinib

Spanish Oncology Genito-Urinary Group

Phase 2

Barcelona, A Coruña, Lugo, Madrid, Toledo, Valencia, Valladolid, Zaragoza

2023-03-07

Active, closed

A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma

NCT05625399Melanoma

DrugsPhesgo·Relatlimab·Nivolumab

Bristol-Myers Squibb

Phase 3

579

A Coruña, Barcelona, Donostia / San Sebastian, Jaén, Madrid, Valencia, Badalona, Las Palmas de Gran Canaria

2023-03-06

Active, closed

A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer

NCT05654623Advanced Breast Cancer

DrugsVepdegestrant·Fulvestrant

Pfizer

Phase 3

624

A Coruña, Elche, Badalona, Barcelona, Bilbao, L'Hospitalet de Llobregat, Donostia / San Sebastian, Lleida

2023-03-03

Recruiting

High Definition Medicine for Solid Tumors Oncology

NCT06590506Metastatic Solid Tumor, Advanced Cancer

Centro Nacional de Investigaciones Oncologicas CARLOS III

Observational

300

A Coruña, Fuenlabrada, Palma de Mallorca, Pamplona, Seville, Barcelona, Cáceres, Madrid

2023-03-02

Active, closed

A Study to Determine the Effect of Triheptanoin Compared With Even-Chain MCT on MCEs in Pediatric Patients With LC-FAOD

NCT05933200Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)

Ultragenyx Pharmaceutical Inc

Phase 3

Barcelona, A Coruña, Madrid

2023-02-28

Active, closed

A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE

NCT05702034Ischemic Stroke; Ischemic Attack, Transient

DrugMilvexian

Janssen Research & Development, LLC

Phase 3

12,523

A Coruña, Albacete, Alicante, Badalona, Barakaldo, Barcelona, Córdoba, Girona

2023-02-15

Recruiting

Long-term Safety and Tolerability of Inclisiran in Participants With HeFH or HoFH Who Have Completed the Pediatric ORION-16, ORION-13, ORION-20, or ORION-19 Studies

NCT05682378Heterozygous or Homozygous Familial Hypercholesterolemia

DrugInclisiran

Novartis Pharmaceuticals

Phase 3

195

Pamplona, Oviedo, A Coruña, Córdoba

2023-02-10

Active, closed

A Study to Test a Medicine (Fitusiran) Injected Under the Skin for Preventing Bleeding Episodes in Male Adolescent or Adult Participants With Severe Hemophilia

NCT05662319Hemophilia

DrugsAntithrombin·Clotting factor concentrates·Fitusiran

Sanofi

Phase 3

A Coruña, Zaragoza

2023-02-01

Active, closed

Treatment of Functionally Non-significant Vulnerable Plaques in Patients With Multivessel ST-elevation Myocardial Infarction The VULNERABLE Trial

NCT05599061Coronary Artery Disease, Coronary Disease, Ischemic Heart Disease

Fundación EPIC

Not applicable

609

L'Hospitalet de Llobregat, A Coruña, Albacete, Alicante, Badalona, Barcelona, Cadiz, Castellon

2023-01-30

Active, closed

Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer

NCT05563220Breast Cancer, Metastatic Breast Cancer

DrugsAlpelisib·Capivasertib·Elacestrant·Everolimus

Stemline Therapeutics, Inc.

Phase 1/2

435

A Coruña, Barcelona, Madrid, Málaga, Pozuelo de Alarcón, Valencia

2023-01-24

By invitation

A Long-Term Follow-Up Study in Severe Hemophilia A Subjects Who Received BMN 270 in a Prior BioMarin Clinical Trial (270-401)

NCT05768386Hemophilia A

BioMarin Pharmaceutical

Observational

172

Seville, A Coruña

2023-01-01

Recruiting

Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)

NCT05712200Atrial Fibrillation (AF)

DrugAbelacimab

Anthos Therapeutics, Inc.

Phase 3

2,500

A Coruña, Almería, Barcelona, Cabra, Granada, Jaén, León, Madrid

2022-12-27

Recruiting

Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas

NCT05751798Solid Advanced Tumor, Lymphoma, NSCLC (Non-small Cell Lung Cancer)

OSE Immunotherapeutics

Phase 1/2

A Coruña, Girona, Málaga

2022-12-20

Recruiting

Efficacy and Safety of XyloCore Peritoneal Dialysis Solution.

NCT03994471End Stage Renal Disease

Iperboreal Pharma Srl

Phase 3

170

A Coruña, Badalona, Barcelona, Girona, Madrid, Oviedo

2022-12-14

Active, closed

A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)

NCT05668988Non-small Cell Lung Cancer

DrugsSunvozertinib·Pemetrexed·Carboplatin

Dizal Pharmaceuticals

Phase 3

324

Barcelona, A Coruña, Girona, Jerez de la Frontera, Madrid, Málaga, Seville, Valencia

2022-12-13

Active, closed

CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG)

NCT05681351Severe Hypertriglyceridemia

DrugOlezarsen

Ionis Pharmaceuticals, Inc.

Phase 3

885

A Coruña, Badalona, Barcelona, Córdoba, Jaén, Madrid, Málaga, Sabadell

2022-12-13

Active, closed

A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer

NCT05488314Carcinoma, Non-Small-Cell Lung

DrugsCapmatinib·Amivantamab

Janssen Research & Development, LLC

Phase 1/2

A Coruña, Alicante, Barcelona, Madrid, Seville, Valencia

2022-12-13

Recruiting

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

NCT05633654Triple Negative Breast Cancer

DrugsXeloda·Sacituzumab Govitecan·Keytruda·Capecitabine

Gilead Sciences

Phase 3

1,514

A Coruña, Badalona, Barakaldo, Barcelona, Castellon, Cáceres, Córdoba, Donostia / San Sebastian

2022-12-12

Active, closed

Romiplostim Plus Dexamethasone vs Dexamethasone in Patients With Newly Diagnosed Primary Immune Thrombocytopenia

NCT05325593Primary Immune Thrombocytopenia

DrugsRomiplostim·Dexamethasone

Fundación Pública Andaluza para la gestión de la Investigación en Sevilla

Phase 3

129

Barcelona, Burgos, A Coruña, Granada, Madrid, Murcia, Málaga, Salamanca

2022-12-02

Active, closed

Olaparib and Durvalumab (MEDI4736) in Patients with Metastatic Pancreatic Cancer and DNA Damage Repair Genes Alterations

NCT05659914Metastatic Pancreatic Cancer

DrugsOlaparib·Durvalumab

Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)

Phase 2

A Coruña, Barcelona, Santander

2022-11-28

Active, closed

NeoadjuVAnt muLti-agENT Chemotherapy or Patritumab Deruxtecan With or Without endocrINE Therapy for High-risk HR+/HER2- Breast Cancer - VALENTINE Trial

NCT05569811Breast Cancer

DrugsPatritumab deruxtecan·Letrozole

SOLTI Breast Cancer Research Group

Phase 2

120

Badalona, Santa Cruz de Tenerife, A Coruña, Fuenlabrada, Móstoles, Badajoz, Barcelona, Bilbao

2022-11-25

Active, closed

Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation

NCT05609578Advanced NSCLC, Metastatic Lung Cancer

DrugAdagrasib

Mirati Therapeutics Inc.

Phase 2

A Coruña, Madrid, Majadahonda, Palma de Mallorca, Seville, Zaragoza

2022-11-22

Recruiting

A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

NCT05498428Carcinoma, Non-small-Cell Lung

DrugsDirect Anticoagulant·LMWH·DOAC·Low molecular weight heparin

Janssen Research & Development, LLC

Phase 2

520

A Coruña, Alicante, Barcelona, Madrid, Málaga, Seville, Valencia

2022-11-11

Active, closed

Study of Pembrolizumab, Lenvatinib and Chemotherapy Combination in First Line Extensive-stage Small Cell Lung Cancer

NCT05384015Small Cell Lung Cancer Extensive Stage

DrugsLenvatinib·Etoposide·Keytruda·Carboplatin

Fundación GECP

Phase 2

Alicante, Badalona, Barcelona, Bilbao, Girona, A Coruña, Lugo, Madrid

2022-11-07

Active, closed

A Study About the Natural History in Adults With BAG3 Dilated Cardiomyopathy (a Type of Heart Disease) (BAG3 DCM)

NCT05981092Cardiomyopathy, Dilated, Bcl-2 Anathogene-3 (BAG3) Dilated Cardiomyopathy (DCM)

Alexion Pharmaceuticals, Inc.

Observational

A Coruña, Madrid, Majadahonda, El Palmar

2022-10-14

Active, closed

Improvement of Immunologic and Molecular Techniques for the Diagnosis and Follow-up of Patients With Thrombotic Thrombocytopenic Purpura

NCT05046717Acquired Thrombotic Thrombocytopenic Purpura

Fundación Española de Hematología y Hemoterapía

Observational

500

A Coruña, Barcelona, Madrid, Valencia

2022-10-13

Active, closed

A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

NCT05556512Obesity, Overweight

DrugTirzepatide

Eli Lilly and Company

Phase 3

15,374

A Coruña, Almería, Alzira, Barcelona, Bilbao, Ferrol, Granada, León

2022-10-11

Active, closed

A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

NCT05514054Breast Neoplasms

DrugsImlunestrant·Tamoxifen·Exemestane·Anastrozole

Eli Lilly and Company

Phase 3

8,000

A Coruña, Alicante, Almería, Badajoz, Barcelona, Bilbao, Burgos, Cáceres

2022-10-04

Recruiting

A Study of EP0031 (Lunbotinib) in Patients With Advanced RET-altered Malignancies

NCT05443126NSCLC

DrugPemetrexed

Ellipses Pharma

Phase 1/2

265

A Coruña, Barcelona, Las Palmas de Gran Canaria, Madrid, Málaga

2022-09-30

Active, closed

Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer

NCT05456685High Grade Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer

DrugsMIRV·Mirvetuximab Soravtansine·Carboplatin

AbbVie

Phase 2

125

A Coruña, Badalona, Córdoba, Pamplona, Badajoz, Barcelona, Lleida, Madrid

2022-09-28

Active, closed

A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy

NCT05450692Advanced or Metastatic Non-Small Cell Lung Cancer

DrugsCeralasertib·Durvalumab·Docetaxel

AstraZeneca

Phase 3

594

A Coruña, Barcelona, Castellon, Córdoba, Hospitalet deLlobregat, Madrid, Málaga, Ourense

2022-09-15

Active, closed

A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus

NCT05531565Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus

DrugLitifilimab

Biogen

Phase 2/3

450

Badalona, Valladolid, Castellon, Alcorcón, Majadahonda, A Coruña, Barcelona, Córdoba

2022-09-13

Active, closed

Study of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer

NCT05403385Metastatic NSCLC - Non-Small Cell Lung Cancer, Locally Advanced NSCLC - Non-Small Cell Lung Cancer

DrugsPemetrexed·Carboplatin

iTeos Therapeutics

Phase 2

Palma de Mallorca, Pamplona, Valencia, A Coruña, Badajoz, Barcelona, Manresa, Ourense

2022-08-26

Active, closed

A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer

NCT05388669Advanced or Metastatic Non-small Cell Lung Cancer

DrugsLazertinib·Amivantamab

Janssen Research & Development, LLC

Phase 3

418

A Coruña, Alicante, Barcelona, Córdoba, Las Palmas de Gran Canaria, Lugo, Madrid, Majadahonda

2022-08-05

Active, closed

A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)

NCT05306340Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer

DrugsGiredestrant·Tamoxifen·Exemestane·Everolimus

Genentech, Inc.

Phase 3

373

A Coruña, Barcelona, Córdoba, Madrid, Murcia, Valencia

2022-08-03

Active, closed

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

NCT05382286Triple Negative Breast Cancer, PD-L1 Positive

DrugsAbraxane·Sacituzumab Govitecan·Taxol·Nab-paclitaxel

Gilead Sciences

Phase 3

443

A Coruña, Barcelona, Bilbao, Lleida, Madrid, Málaga, Murcia, Santa Cruz de Tenerife

2022-07-25

Active, closed

Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

NCT05382299Triple Negative Breast Cancer, PD-L1 Negative

DrugsAbraxane·Sacituzumab Govitecan·Nab-paclitaxel·Gemcitabine

Gilead Sciences

Phase 3

623

A Coruña, Barcelona, Bilbao, Lleida, Madrid, Murcia, Seville, Valencia

2022-07-20

Active, closed

Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma

NCT05352672Melanoma

DrugsFianlimab·Cemiplimab·Keytruda·Pembrolizumab

Regeneron Pharmaceuticals

Phase 3

1,546

Córdoba, Badalona, Barcelona, Donostia / San Sebastian, El Palmar, Oviedo, A Coruña, Girona

2022-07-14

Active, closed

Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Events

NCT05360446Coronary Artery Disease

DrugInclisiran sodium

Novartis Pharmaceuticals

Phase 3

610

A Coruña, Barcelona, Córdoba, Madrid, Salamanca, Valencia

2022-07-08

Active, closed

HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy

NCT05338970Nonsquamous Non-small Cell Lung Cancer, EGFR L858R, EGFR Exon 19 Deletion

DrugPatritumab deruxtecan

Daiichi Sankyo

Phase 3

586

A Coruña, Barcelona, Las Palmas de Gran Canaria, Madrid, Málaga, Santander, Seville

2022-07-08

Recruiting

The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials

NCT05203172Solid Tumors

DrugsVemurafenib·Binimetinib·Encorafenib·Zirabev

Pfizer

Phase 4

210

A Coruña, Badalona, Barcelona, Santander, Lleida, Majadahonda, Madrid, Málaga

2022-07-05

Active, closed

Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis

NCT04991116Psoriatic Arthritis

Sun Pharmaceutical Industries Limited

Phase 3

529

A Coruña, Córdoba, Málaga, Santiago de Compostela, Seville, Valencia

2022-06-30

Recruiting

Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies

NCT05417594Advanced Solid Malignancies

DrugsPalacaparib·Dato-DXd·Trastuzumab deruxtecan·Temozolomide

AstraZeneca

Phase 1/2

695

A Coruña, Barcelona, Málaga, Pozuelo de Alarcón, Sant Cugat del Vallès, Seville

2022-06-24

Active, closed

A Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes in Participants With Severe or Moderate Hemophilia A Without Factor VIII Inhibitors on Emicizumab Prophylaxis

NCT05181618Severe Hemophilia A, Moderate Hemophilia A

DrugEmicizumab

Hoffmann-La Roche

Phase 4

136

A Coruña, Barcelona, Madrid, Málaga

2022-06-20

Active, closed

Study of ctDNA as Prognostic Factor on Resectable Stage IIIA NSCLC Patients Treated With Neoadjuvant Treatment

NCT05382052Non Small Cell Lung Cancer Stage III, Neoadjuvant Treatment

Fundación GECP

Observational

100

A Coruña, Alicante, Badalona, Barcelona, Bilbao, Córdoba, Girona, Pamplona

2022-06-17

Recruiting

A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)

NCT05384626Locally Advanced Solid Tumor, Metastatic Solid Tumor

DrugsNeladalkib·Repaglinide·Itraconazole·Midazolam

Nuvalent Inc.

Phase 1/2

840

A Coruña, Barcelona, Madrid

2022-06-09

Recruiting

A Study of ASP3082 in Adults With Advanced Solid Tumors

NCT05382559Solid Tumor

DrugsNanoparticle Albumin-Bound Paclitaxel·Setidegrasib·Liposomal Irinotecan·Fluorouracil

Astellas Pharma Inc

Phase 1

681

Pamplona, A Coruña, Barcelona, Madrid, Málaga, Seville, Valencia

2022-06-08

Recruiting

Spanish Academy of Dermatology and Venereology (AEDV) Melanoma Registry

NCT05673681Melanoma

Fundación Academia Española de Dermatología

Observational

7,000

Badalona, A Coruña, Barcelona, Córdoba, Las Palmas, León, Madrid, Oviedo

2022-06-01

Active, closed

Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)

NCT05186974Non-small Cell Lung Cancer

DrugsSacituzumab Govitecan·Paraplatin·Keytruda·Cisplatin

Gilead Sciences

Phase 2

193

A Coruña, Badalona, Barcelona, Madrid, Majadahonda, Pamplona, Rincón de la Victoria, Santiago de Compostela

2022-05-30

Active, closed

IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)

NCT05155254Metastatic Melanoma, Unresectable Melanoma

DrugsIO102-IO103·Pembrolizumab

IO Biotech

Phase 3

407

Seville, A Coruña, Barcelona, Madrid, Málaga, Oviedo, Pamplona, Valencia

2022-05-17

Recruiting

Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

NCT05061550Non-small Cell Lung Cancer

DrugsAZD0171·Pemetrexed/Cisplatin·Pemetrexed/Carboplatin·Monalizumab

AstraZeneca

Phase 2

630

A Coruña, Alicante, Barcelona, Córdoba, Madrid, Majadahonda, Málaga, Reus

2022-04-14

Active, closed

Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients

NCT05074810Non Small Cell Lung Cancer, KRAS Activating Mutation

DrugLumakras

Verastem, Inc.

Phase 1/2

153

A Coruña, Madrid, Málaga, Seville

2022-04-12

Recruiting

Clinical Trial of AMG510 in Stage III Unresectable NSCLC KRAS p.G12C Patients and Ineligible for Chemo-radiotherapy

NCT05398094Non-small Cell Lung Cancer Stage III, KRAS P.G12C

DrugSotorasib

Fundación GECP

Phase 2

Alicante, Badalona, Barcelona, Bilbao, Girona, Granada, Jaén, A Coruña

2022-03-21

Active, closed

Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN)

NCT05248646Immunoglobulin A Nephropathy

DrugSibeprenlimab

Otsuka Pharmaceutical Development & Commercialization, Inc.

Phase 3

530

A Coruña, Barakaldo, Barcelona, Bilbao, Córdoba, Ferrol, Madrid, Santander

2022-03-15

Active, closed

Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer

NCT05169567Breast Neoplasm, Neoplasm Metastasis

DrugsAbemaciclib·Fulvestrant

Eli Lilly and Company

Phase 3

368

A Coruña, Palma, Barcelona, El Palmar, Málaga, Pamplona, Reus, Valencia

2022-03-11

Active, closed

Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

NCT05280470Extensive-stage Small-cell Lung Cancer

DrugIfinatamab Deruxtecan

Daiichi Sankyo

Phase 2

187

A Coruña, Barcelona, L'Hospitalet de Llobregat, Madrid, Málaga, Seville

2022-03-09

Active, closed

Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease

NCT05202509Atherosclerotic Cardiovascular Disease

DrugObicetrapib

NewAmsterdam Pharma

Phase 3

9,541

A Coruña, Alicante, Almería, Barcelona, Córdoba, Granada, Madrid, Málaga

2022-02-07

Active, closed

Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)

NCT05173987Endometrial Neoplasms

DrugsTaxotere·Paraplatin·Taxol·Docetaxel

Merck Sharp & Dohme LLC

Phase 3

280

L'Hospitalet de Llobregat, A Coruña, Madrid, Pamplona, Valencia, Barcelona, Seville

2022-02-03

Recruiting

Niraparib With beVAcizumab After Complete cytoreductioN in Patients With ovArian Cancer

NCT05183984Ovarian Cancer

DrugsBevacizumab-awwb·Niraparib

ARCAGY/ GINECO GROUP

Phase 2

390

A Coruña, Barcelona, Cáceres, El Palmar, Murcia, Jerez de la Frontera, Madrid, Málaga, Oviedo

2022-02-01

Active, closed

TocIlizumab in Late/Chronic Active Antibody-mediated Rejection in Kidney Transplant Recipients

NCT04561986Antibody-mediated Rejection

DrugTocilizumab

Vastra Gotaland Region

Phase 3

A Coruña, Barcelona, Valencia

2022-02-01

Recruiting

A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)

NCT05118789Locally Advanced Solid Tumor, Metastatic Solid Tumor

Nuvalent Inc.

Phase 1/2

359

A Coruña, Barcelona, Madrid

2022-01-04

Active, closed

Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.

NCT05038735Breast Cancer

DrugsAlpelisib·Fulvestrant

Novartis Pharmaceuticals

Phase 3

210

Badajoz, Pozuelo de Alarcón, Oviedo, A Coruña, Barcelona, Madrid, Málaga, Zaragoza

2021-12-17

Recruiting

Pathological Response After Neoadjuvant Treatment on NSCLC

NCT05167487Stage IIIA Non-small Cell Lung Cancer

DrugsParaplatin·Cisplatin·Carboplatin

Fundación GECP

Observational

150

A Coruña, Alicante, Badalona, Barcelona, L'Hospitalet de Llobregat, Las Palmas de Gran Canaria, Madrid, Majadahonda

2021-12-13

Active, closed

A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer

NCT05091567Small-Cell Lung Cancer

DrugsLurbinectedin·Tecentriq·Etoposide·Atezolizumab

Hoffmann-La Roche

Phase 3

660

A Coruña, Barcelona, Madrid, Málaga, Seville

2021-11-18

Active, closed

Nivolumab and Ipilimumab Plus Chemotherapy for Patients With Stage IV Lung Cancer With Brain Metastases

NCT05012254Non Small Cell Lung Cancer, Brain Metastases, Adult, Lung Cancer

DrugsYervoy·Paraplatin·Taxol·Ipilimumab

Fundación GECP

Phase 2

Badalona, Barcelona, L'Hospitalet de Llobregat, Castellon, Las Palmas de Gran Canaria, Jaén, A Coruña, León

2021-11-18

Active, closed

Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

NCT05089734Non-Small Cell Lung Cancer

DrugsSacituzumab Govitecan·Docetaxel

Gilead Sciences

Phase 3

603

A Coruña, Badalona, Barakaldo, Barcelona, Cáceres, Girona, Madrid, Málaga

2021-11-17

Recruiting

Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors

NCT05145127Hemophilia A, Hemophilia B

DrugMarstacimab

Pfizer

Phase 3

245

A Coruña, Barcelona, Madrid, Zaragoza

2021-11-17

Active, closed

A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure

NCT04988295Carcinoma, Non-Small-Cell Lung

DrugsLazertinib·Amivantamab·Pemetrexed·Carboplatin

Janssen Research & Development, LLC

Phase 3

776

A Coruña, Barcelona, Las Palmas de Gran Canaria, Madrid, Majadahonda, Málaga, Pamplona, Seville

2021-11-17

Recruiting

Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)

NCT05065216Acute Stroke, Ischemic Stroke, Stroke

DiaMedica Therapeutics Inc

Phase 2/3

728

A Coruña, Badalona, Barcelona, Santiago de Compostela

2021-11-07

Active, closed

Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC

NCT05043090Papillary Renal Cell Carcinoma

DrugsSavolitinib·Sunitinib·Durvalumab

AstraZeneca

Phase 3

148

A Coruña, Barcelona, Córdoba, Madrid, Majadahonda, Málaga, Pamplona, Seville

2021-10-28

Active, closed

A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET

NCT05050942Gastro-enteropancreatic Neuroendocrine Tumor

DrugsCAM2029·Octreotide LAR

Camurus AB

Phase 3

332

A Coruña, Barcelona, Elche, Girona, Madrid, Málaga, Murcia, Oviedo

2021-10-22

Active, closed

A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS)

NCT04861259Atypical Hemolytic Uremic Syndrome

DrugCrovalimab

Hoffmann-La Roche

Phase 3

A Coruña, Barcelona, Seville

2021-10-22

Active, closed

A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)

NCT05104866Breast Cancer

DrugsEribulin·Dato-DXd·Vinorelbine·Capecitabine

AstraZeneca

Phase 3

732

A Coruña, Barcelona, Bilbao (Vizcaya), Huelva, L'Hospitalet de Llobregat, Madrid, Málaga, Seville

2021-10-18

Active, closed

Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED)

NCT04884282Metastatic Non Small Cell Lung Cancer

DrugsTedopi·Docetaxel·Nivolumab

Fondazione Ricerca Traslazionale

Phase 2

105

A Coruña, Barcelona, Madrid, Mataró, Málaga

2021-10-12

Active, closed

A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)

NCT04895696Systemic Lupus Erythematosus

Beeline Medicines Corporation

Phase 2

248

Santander, A Coruña, Barcelona, Madrid, Seville

2021-10-11

Recruiting

MYTHS - MYocarditis THerapy With Steroids

NCT05150704Myocarditis Acute

DrugMethylprednisolone

Niguarda Hospital

Phase 3

288

A Coruña, Barcelona, Madrid, Málaga, Murcia

2021-10-07

Active, closed

A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases

NCT04603807Carcinoma, Non-Small-Cell Lung

DrugsEntrectinib·Crizotinib

Hoffmann-La Roche

Phase 3

217

A Coruña, Barcelona, Madrid, Málaga

2021-09-30

Active, closed

A Study to Compare the Response to Treatment With Abatacept vs Adalimumab, on Background Methotrexate, in Adults With Early, Seropositive, and Shared Epitope-positive Rheumatoid Arthritis and an Inadequate Response to Methotrexate

NCT04909801Rheumatoid Arthritis

DrugsAbatacept·Humira·Adalimumab·Methotrexate

Bristol-Myers Squibb

Phase 3

338

A Coruña, Madrid, Santander

2021-09-15

Active, closed

Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET)

NCT05063786Advanced Breast Cancer

DrugsAlpelisib·Herceptin·Eribulin·Vinorelbine

Spanish Breast Cancer Research Group

Phase 3

A Coruña, Albacete, Alicante, Badajoz, Badalona, Barcelona, Bilbao, Cadiz

2021-09-14

Recruiting

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

NCT05059444Bladder Carcinoma, Ureter Carcinoma, Renal Pelvis Carcinoma, Non-small Cell Lung Cancer

Guardant Health, Inc.

Observational

2,285

A Coruña, Barcelona, Girona, Las Palmas de Gran Canaria, Madrid, Málaga, Sabadell, Santiago de Compostela

2021-09-07

Active, closed

A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease

NCT04929210Arthritis, Psoriatic

DrugsTremfya·Guselkumab

Janssen Research & Development, LLC

Phase 4

411

A Coruña, Barakaldo, Barcelona, Bilbao, Córdoba, Madrid, Málaga, Sabadell

2021-08-30

Active, closed

A Study of Guselkumab and Interleukin-17 (IL-17) Inhibitor Therapies in Participants With Psoriatic Arthritis in Routine Clinical Practice

NCT05049798Arthritis, Psoriatic

DrugsIL-17i·Tremfya·Guselkumab

Janssen Pharmaceutica N.V., Belgium

Observational

1,314

A Coruña, Algeciras / Cadiz, Barcelona, Bilbao, Córdoba, Granada, Madrid, Oviedo

2021-08-25

Active, closed

Chemotherapy-Free pCR-Guided Strategy With Trastuzumab-pertuzumab and T-DM1 in HER2-positive Early Breast Cancer

NCT04733118Early Breast Cancer

MedSIR

Phase 2

393

L'Hospitalet de Llobregat, Córdoba, Reus, A Coruña, Alicante, Badalona, Barcelona, Bilbao

2021-08-05

Recruiting

A Study of 177Lu-FAP-2286 in Advanced Solid Tumors

NCT04939610Solid Tumor

Drug177Lu-FAP-2286

Novartis Pharmaceuticals

Phase 1/2

222

A Coruña, Badalona, Madrid

2021-07-30

Active, closed

A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs

NCT04908202Psoriatic Arthritis

DrugDeucravacitinib

Bristol-Myers Squibb

Phase 3

670

A Coruña, Córdoba, Madrid, Sabadell

2021-07-13

Active, closed

Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)

NCT04964934ER-Positive HER2-Negative Breast Cancer

DrugsCamizestrant·Anastrozole·Abemaciclib·Ribociclib

AstraZeneca

Phase 3

315

A Coruña, Badalona, Barcelona, L'Hospitalet de Llobregat, Madrid, Málaga, Murcia, Sant Joan Despí

2021-06-30

Active, closed

Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)

NCT04793958Advanced Colorectal Cancer, Metastatic Colorectal Cancer

DrugsAdagrasib·MFOLFOX6·Erbitux·Folfox

Mirati Therapeutics Inc.

Phase 3

461

A Coruña, Badalona, Barcelona, Córdoba, LHospitalet de Llobregat, Madrid, Pamplona, Sabadell

2021-06-24

Active, closed

A Study of Guselkumab in Participants With Active Psoriatic Arthritis

NCT04882098Arthritis, Psoriatic

DrugGuselkumab

Janssen Research & Development, LLC

Phase 3

1,054

A Coruña, Córdoba, Madrid, Málaga, Móstoles, Murcia, San Sebastián de los Reyes, Santiago de Compostela

2021-06-17

Recruiting

Trifecta-Heart cfDNA-MMDx Study

NCT04707872Heart Transplant Rejection

University of Alberta

Observational

300

A Coruña

2021-06-01

Active, closed

Prospective Observational Study of Filgotinib in Subjects With Rheumatoid Arthritis

NCT04871919Rheumatoid Arthritis

DrugFilgotinib

Alfasigma S.p.A.

Observational

1,304

A Coruña, Barcelona, Córdoba, Mérida, Murcia, Palma, Pontevedra, Santa Cruz de Tenerife

2021-05-11

Recruiting

Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer

NCT04614103Metastatic Non Small Cell Lung Cancer

DrugLifileucel

Iovance Biotherapeutics, Inc.

Phase 2

170

A Coruña, Barcelona, Córdoba, Madrid, Málaga, Pamplona, Salamanca, Seville

2021-05-07

By invitation

Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM

NCT04848506Symptomatic Hypertrophic Cardiomyopathy (HCM)

DrugAficamten

Cytokinetics

Phase 2/3

900

A Coruña, Barcelona, Madrid, Málaga, Palma, Pontevedra, Salamanca, Seville

2021-05-06

Active, closed

A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease

NCT04777331Parkinsons Disease

DrugPrasinezumab

Hoffmann-La Roche

Phase 2

586

Elche, Sant Cugat del Vallès, Donosti-San Sebastián, A Coruña, Alcorcón, Móstoles, Pozuelo de Alarcón, Pamplona

2021-05-05

Recruiting

A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Upper Limb Spasticity.

NCT04752774Spasticity

DrugsDysport·Corabotase

Ipsen

Phase 1/2

240

A Coruña, Barcelona, Huelva, Madrid, Santiago de Compostela, Seville, Vigo

2021-04-29

Active, closed

Locoregional Control With Radiotherapy of Breast Cancer Patients With MACrometastases Treated With MAstectomy (MACMA)

NCT06378294Breast Cancer

University Hospital A Coruña

Observational

Ferrol, Santiago de Compostela, Vigo, A Coruña, Lugo, Ourense, Pontevedra

2021-04-20

Active, closed

Rectal Tumor Resection Using the UNI-VEC Multichannel Transanal Access Device

NCT06286956Rectal Polyp, Rectal Polyps, Rectal Lesion, Sessile Colonic Polyp

Vecmedical Spain, S.L.

Not applicable

Barcelona, Terrassa, A Coruña, Lugo, Vigo, Madrid, Murcia, Gijón

2021-04-19

Active, closed

ANGiographic Evaluation of Left Main Coronary Artery INtErvention

NCT04604197Coronary Occlusion, Left Main Coronary Artery Disease, Coronary Artery Stenosis, Coronary Disease

Fundación EPIC

Not applicable

400

Badalona, Barakaldo, Donostia / San Sebastian, Málaga, Galdakao, A Coruña, Albacete, Alicante

2021-04-16

Active, closed

A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.

NCT04680052Follicular Lymphoma, Marginal Zone Lymphoma

DrugsTafasitamab·Lenalidomide·Rituximab

Incyte Corporation

Phase 3

654

A Coruña, Alicante, Badalona, Barcelona, Burgos, Gijón, L'Hospitalet de Llobregat, Madrid

2021-04-15

Active, closed

A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura

NCT04683003Thrombotic Thrombocytopenic Purpura (TTP)

DrugTAK-755

Takeda

Phase 3

A Coruña, Barakaldo

2021-04-14

Recruiting

Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)

NCT04728893Hematologic Malignancies, Waldenstroms Macroglobulinaemia, Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukaemia

DrugNemtabrutinib

Merck Sharp & Dohme LLC

Phase 2

490

L'Hospitalet de Llobregat, Salamanca, A Coruña, Alicante, Barcelona, Madrid

2021-04-05

Active, closed

ENdoluminal LIGHT ActivatED Treatment of Upper Tract Urothelial Cancer (ENLIGHTED) Study

NCT04620239Transitional Cell Cancer of Renal Pelvis and Ureter

Steba Biotech S.A.

Phase 3

A Coruña, Barcelona

2021-03-22

Active, closed

Study With Atezolizumab in Combination With Trastuzumab and Vinorelbine in HER2-positive Advanced/Metastatic Breast Cancer

NCT04759248Breast Cancer

DrugsVinorelbine·Trastuzumab·Atezolizumab

SOLTI Breast Cancer Research Group

Phase 2

Granada, Barcelona, L'Hospitalet de Llobregat, Santa Cruz de Tenerife, A Coruña, Alicante, Cáceres, León

2021-03-15

Active, closed

A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer

NCT04486378Colorectal Cancer Stage II, Colorectal Cancer Stage III

DrugAutogene cevumeran

BioNTech SE

Phase 2

327

A Coruña, Ávila, Badalona, Barcelona, Córdoba, Madrid, Majadahonda, Málaga

2021-03-08

Active, closed

A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)

NCT04586231Carcinoma, Renal Cell

DrugsBelzutifan·Cabozantinib·Lenvatinib

Merck Sharp & Dohme LLC

Phase 3

747

A Coruña, Madrid, Barcelona, Seville

2021-02-25

Active, closed

Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation

NCT04685135Metastatic Non Small Cell Lung Cancer, Advanced Non Small Cell Lung Cancer

DrugsAdagrasib·Taxotere·Docetaxel

Mirati Therapeutics Inc.

Phase 3

453

Pamplona, A Coruña, Alicante, Badalona, Barakaldo, Barcelona, Córdoba, Girona

2021-02-23

Active, closed

Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer

NCT04612751Advanced or Metastatic NSCLC

DrugsSabestomig·Volrustomig·Rilvegostomig·Dato-DXd

AstraZeneca

Phase 1

155

A Coruña, Badalona, Barcelona, Madrid, Seville

2021-02-02

Active, closed

A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease (HIBISCUS)

NCT04624659Sickle Cell Disease

DrugEtavopivat

Forma Therapeutics, Inc.

Phase 3

450

A Coruña, Badalona, Barakaldo, Barcelona, Madrid, Seville

2021-01-29

Active, closed

A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma

NCT04657991Melanoma

DrugsBinimetinib·Encorafenib·Keytruda·Pembrolizumab

Pfizer

Phase 3

257

Badalona, Santander, Majadahonda, El Palmar, A Coruña, Barcelona, Córdoba, Jaén

2021-01-15

Recruiting

Secukinumab Open Label Roll-over Extension Protocol

NCT04638647Autoimmunity, Inflammation

DrugSecukinumab

Novartis Pharmaceuticals

Phase 4

1,000

Santiago Compostela, Málaga, L'Hospitalet de Llobregat, Bilbao, Santander, Vigo, A Coruña, Madrid

2020-12-22

Active, closed

A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy

NCT04640623Urinary Bladder Neoplasms

DrugsTAR-200·Cetrelimab

Janssen Research & Development, LLC

Phase 2

220

A Coruña, Badalona, Barcelona, Cadiz, Granada, Jerez de la Frontera, Madrid, Málaga

2020-12-18

Active, closed

Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy

NCT04655976Lung Cancer, Non-Small Cell

DrugsCobolimab·Dostarlimab·Docetaxel

GlaxoSmithKline

Phase 2/3

758

A Coruña, Badalona, Barcelona, Burgos, Córdoba, Las Palmas de Gran Canar, Madrid, Málaga

2020-12-08

Active, closed

A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder

NCT04658862Urinary Bladder Neoplasms

DrugsTAR-200·Cetrelimab·Gemcitabine·Cisplatin

Janssen Research & Development, LLC

Phase 3

518

A Coruña, Badalona, Barcelona, Granada, Jerez de la Frontera, Madrid, Sabadell, Santander

2020-12-07

Active, closed

A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)

NCT04622319HER2-Positive Primary Breast Cancer, Residual Invasive Breast Cancer

DrugsTrastuzumab emtansine·Trastuzumab deruxtecan

Daiichi Sankyo

Phase 3

1,600

Bilbao, El Palmar, Reus, A Coruña, Alcorcón, Alicante, Badajoz, Barcelona

2020-12-04

Recruiting

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

NCT04613596Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer

DrugsAdagrasib·Pembrolizumab

Mirati Therapeutics Inc.

Phase 2/3

626

Pamplona, A Coruña, Badalona, Barcelona, Bilbao, Burgos, Jerez de la Frontera, Las Palmas de Gran Canaria

2020-12-02

Active, closed

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)

NCT04544436Multiple Sclerosis

DrugsOcrelizumab·Methylprednisolone

Hoffmann-La Roche

Phase 3

864

A Coruña, Pozuelo de Alarcón, Vigo, Barcelona, Cadiz, Málaga

2020-11-26

Active, closed

RADIANT: A Study of Radium-223 Dichloride (Xofigo) vs Enzalutamide or Abiraterone (ARPIs, Androgen Receptor Pathway Inhibitors) in Patients With Prostate Cancer That Has Spread to the Bones (mCRPC, Metastatic Castration-Resistant Prostate Cancer)

NCT04597125Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Bayer

Phase 4

654

Santiago de Compostela, Palma de Mallorca, Badalona, Castellon, Majadahonda, Oviedo, A Coruña, Barcelona

2020-11-09

Active, closed

Sacituzumab Govitecan in Primary HER2-negative Breast Cancer

NCT04595565HER2-negative Breast Cancer, Triple Negative Breast Cancer

DrugsXeloda·Sacituzumab Govitecan·Paraplatin·Capecitabine

GBG Forschungs GmbH

Phase 3

1,332

Barakaldo, A Coruña, Albacete, Alcorcón, Alcoy, Alicante, Badalona, Barcelona

2020-10-28

Active, closed

A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis

NCT04544449Multiple Sclerosis, Primary Progressive

DrugsFenebrutinib·Ocrelizumab

Hoffmann-La Roche

Phase 3

985

A Coruña, Lleida, Pozuelo de Alarcón, Vigo, Barcelona, Cadiz, Madrid, Málaga

2020-10-26

Active, closed

A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions

NCT04538664Carcinoma, Non-Small-Cell Lung

DrugsAmivantamab·Pemetrexed·Carboplatin

Janssen Research & Development, LLC

Phase 3

308

A Coruña, Badalona, Barcelona, Burgos, Madrid, Majadahonda, Málaga, Pamplona

2020-10-13

Active, closed

A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)

NCT04546009Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer

DrugsGiredestrant·Palbociclib·Letrozole

Hoffmann-La Roche

Phase 3

992

L'Hospitalet de Llobregat, Donostia / San Sebastian, Pozuelo de Alarcón, A Coruña, Barcelona, Madrid, Seville, Valencia

2020-10-09

Active, closed

Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients

NCT04293393Early Breast Cancer

DrugsLeuprolide·Goserelin·Pegylated liposomal doxorubicin·Abemaciclib

Spanish Breast Cancer Research Group

Phase 2

200

Santiago de Compostela, L'Hospitalet de Llobregat, Santander, Castellon, San Sebastián, Vigo, A Coruña, Alicante

2020-10-02

Active, closed

A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

NCT04487080Carcinoma, Non-Small-Cell Lung

DrugsLazertinib·Amivantamab·Osimertinib

Janssen Research & Development, LLC

Phase 3

1,074

A Coruña, Badalona, Barcelona, Burgos, Girona, Madrid, Majadahonda, Málaga

2020-09-30

Active, closed

A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC)

NCT04497844Prostatic Neoplasms

DrugsAbiraterone acetate·Prednisone

Janssen Research & Development, LLC

Phase 3

696

A Coruña, Barcelona, Castellon, Girona, Jerez de la Frontera, Madrid, Málaga, Sabadell

2020-09-23

Active, closed

Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis

NCT04468984Myelofibrosis (MF)

DrugsNavitoclax·Ruxolitinib

AbbVie

Phase 3

330

A Coruña, Santiago de Compostela, Badalona, Las Palmas de Gran Canaria, Oviedo, Barcelona, Granada, Madrid

2020-08-31

Active, closed

Personalized Therapy Study - HFRS (TriageHF) Post Approval Study

NCT04489225Heart Failure

Medtronic

Observational

2,200

A Coruña, Granada, Madrid, Salamanca, Santa Cruz de Tenerife, Santiago, Valladolid

2020-08-01

Active, closed

Personalized Therapy Study - Intrinsic Antitachycardia Pacing Post-Approval Study (iATP PAS)

NCT04496518Ventricular Tachycardia

Medtronic

Observational

2,200

A Coruña, Granda, Madrid, Salamanca, Santa Cruz de Tenerife, Santiago, Valladolid

2020-08-01

Active, closed

Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer

NCT04494425Advanced or Metastatic Breast Cancer

DrugsTrastuzumab deruxtecan·Nab-paclitaxel·Capecitabine·Paclitaxel

AstraZeneca

Phase 3

866

A Coruña, Barcelona, Córdoba, El Palmar, Madrid, San Sebastián, Seville, Valencia

2020-07-24

Active, closed

Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naïve Subjects With Active Psoriatic Arthritis II (INSPIRE 2)

NCT04314531Active Psoriatic Arthritis

Sun Pharmaceutical Industries Limited

Phase 3

296

A Coruña, Córdoba, Madrid, Seville

2020-07-01

Active, closed

The PreQ-20 TRIAL, a Prospective Cohort Study of Patients Undergoing Prepectoral Breast Reconstruction

NCT04642508Breast Cancer, Quality of Life, Surgery--Complications

University Hospital A Coruña

Not applicable

A Coruña

2020-06-22

Active, closed

Clinical Utility of Liquid Biopsy in Brigatinib ALK+ Patients

NCT04223596Lung Cancer, NSCLC, NSCLC Stage IIIB, NSCLC Stage IV

DrugBrigatinib

Fundación GECP

Phase 2

A Coruña, Alicante, Málaga, Palma de Mallorca, Badalona, L'Hospitalet de Llobregat, Barcelona, Las Palmas de Gran Canaria

2020-05-04

Active, closed

Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer

NCT04305496Locally Advanced (Inoperable) or Metastatic Breast Cancer

DrugsCapivasertib·Fulvestrant

AstraZeneca

Phase 3

818

A Coruña, Barcelona, Córdoba, Hosp de Llobregat(Barcelona), Jaén, La Laguna (Tenerife), Lleida, Madrid

2020-04-16

Active, closed

DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer

NCT04042701Breast Cancer, Non-small Cell Lung Carcinoma

DrugsTrastuzumab deruxtecan·Keytruda·Pembrolizumab

Daiichi Sankyo

Phase 1

115

A Coruña, Barcelona, Las Palmas de Gran Canaria, Madrid, Seville, Zaragoza

2020-02-10

Active, closed

A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Arterial Hypertension

NCT04175600Hypertension, Pulmonary

DrugSelexipag

Actelion

Phase 3

138

A Coruña, Barcelona, Esplugues de Llobregat, Madrid, Seville

2020-01-16

Active, closed

TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations

NCT04129502Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

DrugsMobocertinib·Pemetrexed·Cisplatin·Carboplatin

Takeda

Phase 3

354

L'Hospitalet de Llobregat, A Coruña, Alicante, Barcelona, Córdoba, Madrid, Valencia

2020-01-10

Active, closed

A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer

NCT04165317Non-muscle Invasive Bladder Cancer

DrugsSasanlimab·Bacillus Calmette-Guerin

Pfizer

Phase 3

1,068

Badalona, Granollers, L'Hospitalet de Llobregat, Majadahonda, Pamplona, Reus, A Coruña, Barcelona

2019-12-30

Active, closed

A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma

NCT04194775Hepatocellular Carcinoma

DrugLenvatinib

CStone Pharmaceuticals

Phase 3

534

A Coruña, Ourense, Majadahonda, Oviedo, Ávila, Barcelona, Burgos, Girona

2019-12-13

Recruiting

Treatment of Breakpoint Cluster Region-Abelson (BCR-ABL) Negative ALL in Adults

NCT04179929Acute Lymphoblastic Leukemia

PETHEMA Foundation

Not applicable

300

Badalona, A Coruña, Albacete, Alicante, Ávila, Barcelona, Bellvitge, Bilbao

2019-11-25

Active, closed

Registry Study of Pregnancy and Breast Cancer

NCT04603820Breast Cancer and Pregnancy

Spanish Breast Cancer Research Group

Observational

866

Palma de Mallorca, Badalona, Terrassa, Bilbao, Santa Cruz de Tenerife, A Coruña, Las Palmas de Gran Canaria, Leganés

2019-11-18

Active, closed

A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer

NCT04036682Non Small Cell Lung Cancer, EGFR Exon 20 Mutation

DrugZipalertinib

Cullinan Therapeutics Inc.

Phase 1/2

284

A Coruña, Barcelona, Las Palmas, Madrid, Málaga, Pamplona, Valencia

2019-10-31

Active, closed

Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma

NCT04099251Melanoma

DrugsOpdivo·Nivolumab

Bristol-Myers Squibb

Phase 3

790

Barcelona, A Coruña, Badalona, Madrid, Málaga, Santander, Valencia

2019-10-28

Active, closed

Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors

NCT04041310Solid Tumor, Adult

DrugsKeytruda·Pembrolizumab

Nouscom SRL

Phase 1/2

115

A Coruña, Barcelona, Córdoba, Granada, Madrid, Pamplona, Salamanca, Santander

2019-10-21

Active, closed

Safety and Efficacy of AT-001 in Patients With Diabetic Cardiomyopathy

NCT04083339Diabetic Cardiomyopathies

Applied Therapeutics, Inc.

Phase 3

675

Badalona, El Palmar, A Coruña, Barcelona, Córdoba, Seville, Valencia

2019-09-20

Active, closed

Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer

NCT03820830Breast Cancer Recurrent

DrugPalbociclib

ETOP IBCSG Partners Foundation

Phase 3

405

San Cristóbal de La Laguna, A Coruña, Alicante, Barcelona, Bilbao, Girona, Madrid, Málaga

2019-08-27

Recruiting

Pan Tumor Rollover Study

NCT03899155Cancer

DrugsRucaparib·Sunitinib·Trametinib·Relatlimab

Bristol-Myers Squibb

Phase 2

1,500

Donostia / San Sebastian, Majadahonda, Pamplona, A Coruña, Alicante, Badalona, Barcelona, Burgos

2019-08-09

Active, closed

A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)

NCT04008030Metastatic Colorectal Cancer

DrugsFluorouracil·Leucovorin·Ipilimumab·Irinotecan

Bristol-Myers Squibb

Phase 3

839

Badalona, A Coruña, Barcelona, Madrid, Málaga, Seville, Valencia

2019-08-05

Active, closed

Functional Assessment in Elderly MI Patients With Multivessel Disease

NCT03772743Myocardial Infarction

Consorzio Futuro in Ricerca

Not applicable

1,445

A Coruña, Ciudad Real, Lugo, Madrid, Santiago de Compostela, Valencia, Valladolid, Vigo

2019-07-15

Active, closed

A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor

NCT04008797Endometrial Neoplasms, Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms

DrugsE7386·Doxorubicin·Lenvatinib·Paclitaxel

Eisai Inc.

Phase 1/2

301

A Coruña, Barcelona, Jaén, Madrid

2019-07-11

Active, closed

Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)

NCT03944772Non-Small Cell Lung Cancer

DrugsNecitumumab·Gefitinib·Savolitinib·Selpercatinib

AstraZeneca

Phase 2

247

A Coruña, Barcelona, Madrid, Seville

2019-06-25

Active, closed

A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy

NCT03767244Prostatic Neoplasms

DrugApalutamide

Janssen Research & Development, LLC

Phase 3

2,517

A Coruña, Barcelona, Cadiz, Castellon, Jerez de la Frontera, Madrid, Manacor, Málaga

2019-06-11

Active, closed

NADIM II: Neo-Adjuvant Immunotherapy

NCT03838159Non Small Cell Lung Cancer

DrugsParaplatin·Taxol·Opdivo·Nivolumab

Fundación GECP

Phase 2

Alicante, Badalona, Barcelona, L'Hospitalet de Llobregat, Córdoba, Girona, Las Palmas de Gran Canaria, A Coruña

2019-05-15

Active, closed

A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes

NCT03811561Diabetes Mellitus, Type 2

DrugSemaglutide

Novo Nordisk A/S

Phase 3

1,500

A Coruña, Barcelona, L'Hospitalet de Llobregat, Pamplona, Seville, Valencia

2019-05-08

Active, closed

A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy

NCT03675308Psoriatic Arthritis

DrugsSkyrizi·Risankizumab

AbbVie

Phase 3

964

Badalona, Sabadell, A Coruña, Almería, Barcelona, Madrid, Valencia

2019-03-25

Active, closed

A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer

NCT03748641Castration-Resistant Prostatic Cancer

DrugsAbiraterone acetate·Niraparib·Prednisone

Janssen Research & Development, LLC

Phase 3

765

A Coruña, Barcelona, Jerez de la Frontera, Madrid, Málaga, Pozuelo de Alarcón, Sabadell, Santander

2019-01-25

Active, closed

Atezolizumab Plus One-year BCG Bladder Instillation in BCG-naive High-risk Non-muscle Invasive Bladder Cancer Patients

NCT03799835Bladder Cancer

DrugsTecentriq·Atezolizumab

UNICANCER

Phase 3

517

A Coruña, Cadiz, Madrid, Murcia, Santa Cruz de Tenerife

2019-01-17

Active, closed

Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)

NCT03725059Breast Cancer

DrugsEpirubicin·Adriamycin·Cytoxan·Taxol

Merck Sharp & Dohme LLC

Phase 3

1,240

L'Hospitalet de Llobregat, A Coruña, Pozuelo de Alarcón, Madrid, Valencia, Barcelona, Jaén, Seville

2018-12-27

Active, closed

A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW).

NCT03653507Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma

DrugsZolbetuximab·Capecitabine·Oxaliplatin

Astellas Pharma Global Development, Inc.

Phase 3

507

A Coruña, Barcelona, Elche, Madrid, Málaga, Pamplona, Valencia

2018-11-28

Active, closed

Treatment for Elderly Fit Newly Diagnosed Multiple Myeloma Patients Aged Between 65 and 80 Years

NCT03742297Newly Diagnosed Multiple Myeloma

DrugsMelphalan·Carfilzomib·Bortezomib·Daratumumab

PETHEMA Foundation

Phase 3

462

A Coruña, Albacete, Alicante, Badalona, Barcelona, Bilbao, Cáceres, Córdoba

2018-10-22

Active, closed

Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer

NCT03595592Invasive Breast Cancer

DrugsPerjeta·Herceptin·Tecentriq·Pertuzumab

Fondazione Michelangelo

Phase 3

650

A Coruña, Alcoy, Alicante, Badajoz, Barcelona, Bilbao, Cáceres, Granada

2018-09-07

Active, closed

A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors

NCT03530397Selected Advanced Solid Tumors

DrugsVolrustomig·Nab-paclitaxel·Pemetrexed·Paclitaxel

MedImmune LLC

Phase 1

400

A Coruña, Barcelona, Majadahonda, Málaga, Pamplona, Valencia

2018-04-24

Active, closed

A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma

NCT03470922Melanoma

DrugsRelatlimab·Nivolumab

Bristol-Myers Squibb

Phase 2/3

714

A Coruña, Barcelona, Madrid, San Sabastian Gipuzkoa, Seville

2018-04-11

Active, closed

A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433

NCT03345823Crohn's Disease

DrugUpadacitinib

AbbVie

Phase 3

747

Palma de Mallorca, Santander, Las Palmas de Gran Canaria, Pamplona, A Coruña, Barcelona, Girona, Huelva

2018-03-21

Recruiting

Long-Term Follow-up Study of Early Stage Breast Cancer Patients Included in GEICAM Studies

NCT03390894Invasive Breast Cancer Early Stages

Spanish Breast Cancer Research Group

Observational

8,000

Pamplona, Avilés, San Cristóbal de La Laguna, A Coruña, Albacete, Alicante, Badajoz, Badalona

2018-01-18

Active, closed

A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)

NCT03148418Cancer

DrugsTecentriq·Avastin·Atezolizumab·Bevacizumab

Hoffmann-La Roche

Phase 3

382

Palma de Mallorca, Córdoba, A Coruña, Las Palmas de Gran Canaria, Pamplona, Barcelona, Cáceres, Jaén

2017-09-20

Active, closed

Personalized Therapy Study - Attain Stability Quad Post-Approval Study

NCT04024943Heart Failure

Medtronic

Observational

1,092

A Coruña, Granada, Madrid, Salamanca, Santa Cruz de Tenerife, Santiago de Compostela, Valladolid

2017-08-21

Active, closed

Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive Breast Cancer: FDG-PET Response-adapted Strategy.

NCT03161353Breast Cancer

DrugsPerjeta·Herceptin·Tamoxifen·Pertuzumab

MedSIR

Phase 2

377

Badalona, L'Hospitalet de Llobregat, Castelló, Jaén, Málaga, Reus, A Coruña, Barcelona

2017-06-26

Active, closed

A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC

NCT03052608Carcinoma, Non-Small-Cell Lung

DrugsCrizotinib·Lorlatinib

Pfizer

Phase 3

296

L'Hospitalet de Llobregat, Las Palmas de Gran Canaria, Majadahonda, Pamplona, A Coruña, Barcelona, Girona, Madrid

2017-04-27

Active, closed

Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN)

NCT03043872Small Cell Lung Carcinoma Extensive Disease

DrugsTremelimumab·Etoposide·Durvalumab·Cisplatin

AstraZeneca

Phase 3

987

A Coruña, Badajoz, Badalona, Barcelona, Madrid, Santander, Valencia, Zaragoza

2017-03-27

Active, closed

Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer

NCT03036098Urothelial Cancer

DrugsYervoy·Ipilimumab·Opdivo·Nivolumab

Bristol-Myers Squibb

Phase 3

1,314

A Coruña, Barcelona, Madrid, Santander, Seville, Valencia

2017-03-24

Active, closed

A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)

NCT03006068Ulcerative Colitis (UC)

DrugUpadacitinib

AbbVie

Phase 3

950

A Coruña, Santiago de Compostela, Santander, Las Palmas de Gran Canaria, Barcelona, Córdoba, Madrid, Salamanca

2017-01-31

Active, closed

An Observational Prospective Long-term Exposure Registry of Adult Patients With Moderate-to-Severe Ulcerative Colitis

NCT02808780Ulcerative Colitis

Janssen Biotech, Inc.

Observational

535

A Coruña, Barcelona, Córdoba, Fuenlabrada, Huelva, Madrid, Majadahonda, San Sebastián de los Reyes

2016-12-16

Active, closed

Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants

NCT02938520HIV Infections

DrugsCabotegravir (CAB)·Rilpivirine (RPV)·Rilpivirine·Cabotegravir

ViiV Healthcare

Phase 3

631

A Coruña, Barcelona, Bilbao, Elche Alicante, Ferrol, Granada, La Laguna Santa Cruz, Madrid

2016-10-27

Active, closed

A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer

NCT02716116Carcinoma, Non-Small-Cell Lung

DrugMobocertinib

Takeda

Phase 1/2

334

A Coruña, Barcelona

2016-06-16

Active, closed

Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer

NCT02609776Non-Small-Cell Lung Cancer

DrugsLazertinib·Amivantamab·Pemetrexed·Carboplatin

Janssen Research & Development, LLC

Phase 1

751

A Coruña, Barcelona, Madrid, Málaga, Santander, Seville

2016-05-24

Recruiting

Diagnostic and Therapeutic Applications of Microarrays in Heart Transplantation

NCT02670408Cardiac Transplant Disorder

University of Alberta

Observational

900

A Coruña

2016-01

Active, closed

Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study

NCT02584933ALK Positive Malignancies

DrugCeritinib

Novartis Pharmaceuticals

Phase 4

233

A Coruña, Barcelona, Madrid, Málaga

2015-12-11

Active, closed

A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate

NCT02629159Rheumatoid Arthritis

DrugsHumira·Adalimumab·Upadacitinib

AbbVie

Phase 3

1,629

Santander, A Coruña, Córdoba, Santiago de Compostela

2015-12-01

Active, closed

AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy.

NCT02511106Stage IB-IIIA Non-small Cell Lung Carcinoma

DrugOsimertinib

AstraZeneca

Phase 3

682

A Coruña, Barcelona, Donostia / San Sebastian, Elche, Las Palmas de Gran Canaria, Madrid, Majadahonda, Málaga

2015-10-21

Active, closed

PALbociclib CoLlaborative Adjuvant Study

NCT02513394Breast Cancer

DrugPalbociclib

Alliance Foundation Trials, LLC.

Phase 3

5,796

A Coruña, Alicante, Badalona, Barcelona, Burgos, Castellon, Cáceres, Córdoba

2015-08

Active, closed

Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)

NCT02453282Non-Small-Cell Lung Carcinoma NSCLC

DrugsTremelimumab·Durvalumab·Pemetrexed·Gemcitabine

AstraZeneca

Phase 3

1,118

A Coruña, Alicante, Barcelona, Girona, Jaén, León, Madrid, Majadahonda

2015-07-21

Active, closed

Micra Transcatheter Pacing System Post-Approval Registry

NCT02536118Bradycardia

Medtronic

Observational

3,100

A Coruña, Barcelona, Santiago de Compostela, Toledo, Vitoria-Gasteiz

2015-07

Active, closed

A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer

NCT02152631Non Small Cell Lung Cancer

DrugsErlotinib·Abemaciclib

Eli Lilly and Company

Phase 3

453

A Coruña, Barcelona, L'Hospitalet de Llobregat, Madrid, Málaga, Seville, Valencia

2014-10-03

Active, closed

A Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn's Disease (CD)

NCT02130362Crohn's Disease

AbbVie

Observational

1,446

A Coruña, Ferrol, Santiago de Compostela, Palma de Mallorca, Badalona, Esplugues de Llobregat, Sabadell, Leganés

2014-08-28

Active, closed

Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer

NCT02032823Breast Cancer

DrugOlaparib

AstraZeneca

Phase 3

1,837

A Coruña, Ávila, Badajoz, Badalona, Barcelona, Castellon, Cáceres, Córdoba

2014-04-22

Recruiting

AURORA: Aiming to Understand the Molecular Aberrations in Metastatic Breast Cancer.

NCT02102165Metastatic Breast Cancer

Jules Bordet Institute

Not applicable

1,000

A Coruña, Barcelona, Castellon, Cáceres, Lleida, Madrid, Seville, Valencia

2014-04

Active, closed

A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer

NCT01946204Prostatic Neoplasms

DrugApalutamide

Aragon Pharmaceuticals, Inc.

Phase 3

1,207

A Coruña, Badalona, Barcelona, Castellon, Girona, Guadalajara, Jerez de la Frontera, Las Palmas de Gran Canaria

2013-10-14

Recruiting

Lysosomal Acid Lipase (LAL) Deficiency Registry

NCT01633489Lysosomal Acid Lipase Deficiency, Cholesterol Ester Storage Disease, Wolman Disease, Acid Cholesteryl Ester Hydrolase Deficiency, Type 2

Alexion Pharmaceuticals, Inc.

Observational

300

Santiago de Compostela, Barakaldo, Logroño, Burela de Cabo, Málaga, Oviedo, Reus, A Coruña

2013-05-30

Active, closed

A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)

NCT01848561Ulcerative Colitis (UC)

AbbVie

Observational

8,250

A Coruña, Ferrol, Santiago de Compostela, Elche, Sant Joan d'Alacant, Manacor, Palma de Mallorca, Badalona

2013-04-29

Recruiting

Product Surveillance Registry

NCT01524276Cardiac Rhythm Disorders, Urological Disorders, Neurological Disorders, Cardiovascular Disorders

Medtronic

Observational

100,000

A Coruña, Córdoba, Elche, Girona, Granada, L'Hospitalet de Llobregat, Madrid, Málaga

2012-01

Active, closed

Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer

NCT01272037Breast Ductal Carcinoma In Situ, Invasive Breast Carcinoma, Multicentric Breast Carcinoma, Multifocal Breast Carcinoma

DrugsTamoxifen Citrate·Tamoxifen·Exemestane·Anastrozole

National Cancer Institute (NCI)

Phase 3

5,018

A Coruña, Albacete, Barcelona, Castellon, Cáceres, Donostia / San Sebastian, Girona, Madrid

2011-02-28

Active, closed

Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.

NCT00099437Breast Cancer

DrugFulvestrant

AstraZeneca

Phase 3

736

A Coruña, Madrid, Málaga, Oviedo, Salamanca, Seville

2005-02-13

Active, closed

Effectiveness of Localized Prostate Cancer Treatments

NCT01492751Prostate Cancer

Fundacion IMIM

Observational

500

Hospitalet Llobregat,, L'Hospitalet de Llobregat, Sant Cugat del Vallès, San Sebastián, A Coruña, Barcelona, Madrid, Málaga

2003-04

Recruiting

Fabry Disease Registry & Pregnancy Sub-registry

NCT00196742Fabry Disease

Genzyme, a Sanofi Company

Observational

9,000

A Coruña, Barcelona, Barakaldo, L'Hospitalet de Llobregat, Vigo, Tarragona

2001-07-31

Recruiting

Computerized Registry of Patients With Venous Thromboembolism (RIETE)

NCT02832245Venous Thromboembolism

Manuel Monreal

Observational

120,000

A Coruña, Cee, Ferrol, Ribeira, Santiago de Compostela, Albacete, Alicante, Elche

2001-03

Recruiting

International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry

NCT00358943Gaucher Disease, Cerebroside Lipidosis Syndrome, Glucocerebrosidase Deficiency Disease, Glucosylceramide Beta-Glucosidase Deficiency Disease

Genzyme, a Sanofi Company

Observational

12,000

A Coruña, Barcelona, Alcorcón, Vigo, Seville, Madrid, Sabadell, Valencia

1991-04-01

Recruiting

Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products

NCT00271180Arrhythmia, Bradycardia, Heart Failure, Sinus Tachycardia

Medtronic

Observational

20,000

A Coruña, Barcelona, Córdoba, Girona, Granada, Madrid, Palma de Mallorca, Salamanca

1983-01

Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Spanish investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 12 October 2026. https://priyalifescience.com/clinical-trials-spain/city/a-coru-a

Query this register directly

GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Spain and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,875 studies in total at the last sync on 11 Oct 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 485 of those studies with a site in A Coruña.

How many clinical trials are recruiting in A Coruña?

229 of the 485 studies on this page are recruiting new participants as of the 11 Oct 2026, 03:18 UTC sync. A further 8 have not yet opened recruitment, 244 are active but closed to new participants, and 4 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (A Coruña), 485 studies
Phase	Studies	Recruiting	Share
Phase 3	274	117	56.5%
Phase 2	75	34	15.5%
Observational	53	32	10.9%
Not applicable	25	13	5.2%
Phase 1/2	21	14	4.3%
Phase 2/3	18	11	3.7%
Phase 4	10	5	2.1%
Phase 1	9	3	1.9%

Most active sponsors

Lead sponsors with the most studies (A Coruña)
Lead sponsor	Studies	Recruiting
AstraZeneca	43	22
Janssen Research & Development, LLC	24	6
Merck Sharp & Dohme LLC	18	13
Eli Lilly and Company	17	5
AbbVie	16	6
Hoffmann-La Roche	16	5
Bristol-Myers Squibb	14	5
Novartis Pharmaceuticals	13	6
Pfizer	13	8
Amgen	10	2

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.